<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1512246418
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIMZIA 200 mg Solution for Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CERTOLIZUMAB PEGOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2839.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Vetter Pharma-Fertigung GmbH &amp; Co.KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Vetter Pharma-Fertigung GmbH & Co.KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            U.C.B.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cimzia contains the active substance certolizumab pegol, a human antibody fragment. Antibodies are proteins that specifically recognise and bind to other proteins. Cimzia binds to a specific protein called tumour necrosis factor &alpha; (TNF&alpha;). Thereby this TNF&alpha; is blocked by Cimzia and this decreases inflammation diseases such as in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and psoriasis. Medicines that bind to TNF&alpha; are also called TNF blockers.</p><p>&nbsp;</p><p>Cimzia is used in adults for the following inflammatory diseases:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rheumatoid arthritis,</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>axial spondyloarthritis</strong> (including ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>psoriatic arthritis</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>plaque psoriasis</strong></p><p>&nbsp;</p><p><strong>Rheumatoid arthritis</strong></p><p>Cimzia is used to treat rheumatoid arthritis. Rheumatoid arthritis is an inflammatory disease of the joints. If you have moderate to severe active rheumatoid arthritis, you may first be given other medicines usually methotrexate. If you do not respond well enough to these medicines, you will be given Cimzia in combination with methotrexate to treat your rheumatoid arthritis. If your doctor determines that methotrexate is inappropriate, Cimzia can be given alone.</p><p>&nbsp;</p><p>Cimzia in combination with methotrexate can also be used to treat severe, active and progressive rheumatoid arthritis without previous use of methotrexate or other medicines.</p><p>&nbsp;</p><p>Cimzia, which you will take in combination with methotrexate , is used to:</p><ul><li>reduce the signs and symptoms of your disease,</li><li>slow down the damage to the cartilage and bone of the joints caused by the disease,</li><li>improve your physical function and performance of daily tasks.</li></ul><p>&nbsp;</p><p><strong>Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis</strong></p><p>Cimzia is used to treat severe active ankylosing spondylitis and axial spondyloarthritis<s> </s>without radiographic evidence of ankylosing spondylitis (sometimes referred to as non-radiographic axial spondyloarthritis). These diseases are inflammatory diseases of the spine. If you have ankylosing spondylitis or non-radiographic axial spondyloarthritis you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Cimzia to:</p><ul><li>reduce the signs and symptoms of your disease,</li><li>improve your physical function and performance of daily tasks.</li></ul><p>&nbsp;</p><p><strong>Psoriatic arthritis</strong></p><p>Cimzia is used to treat active psoriatic arthritis. Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis. If you have active psoriatic arthritis you will first be given other medicines, usually methotrexate. If you do not respond well enough to these medicines, you will be given Cimzia in combination with methotrexate to:</p><ul><li>reduce the signs and symptoms of your disease,</li><li>improve your physical function and performance of daily tasks.</li></ul><p>If your doctor determines that methotrexate is inappropriate, Cimzia can be given alone.</p><p>&nbsp;</p><p><strong>Plaque psoriasis</strong></p><p>Cimzia is used to treat moderate to severe plaque psoriasis. Plaque psoriasis is an inflammatory disease of the skin, and can also affect your scalp and nails.</p><p>Cimzia is used to reduce skin inflammation and other signs and symptoms of your disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do NOT use Cimzia</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>ALLERGIC</strong> (hypersensitive) to certolizumab pegol or any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a severe infection, including active <strong>TUBERCULOSIS</strong> (TB).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have moderate to severe <strong>HEART FAILURE</strong>. Tell your doctor if you have had or have a serious heart condition.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Tell your doctor before treatment with Cimzia if any of the following applies to you:</p><p><em>Allergic reactions</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience <strong>ALLERGIC REACTIONS</strong> such as chest tightness, wheezing, dizziness, swelling or rash, stop using Cimzia and contact your doctor <strong>IMMEDIATELY</strong>. Some of these reactions could occur after the first administration of Cimzia.</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had an allergic reaction to latex.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Infections</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had <strong>RECURRENT or OPPORTUNISTIC INFECTIONS</strong> or other conditions that increase the risk of infections (such as treatment with immunosuppressants, which are medicines that could reduce your ability to fight infections).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an infection or if you develop symptoms such as fever, wounds, tiredness or dental problems. You might get an infection more easily while you are being treated with Cimzia, including serious, or in rare cases, life-threatening infections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TUBERCULOSIS (TB) </strong>cases have been reported in patients treated with Cimzia, your doctor will check you for signs and symptoms of tuberculosis before starting Cimzia. This will include a thorough medical history, a chest X‑ray and a tuberculin test. If latent (inactive) tuberculosis is diagnosed, you might be required to receive appropriate anti‑tuberculosis medicines before starting Cimzia. In rare occasions tuberculosis can develop during therapy even if you have received preventive treatment for tuberculosis. It is very important that you tell your doctor if you have ever had tuberculosis, or if you have been in close contact with someone who has had tuberculosis. If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy with Cimzia tell your doctor immediately.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are at risk of or are a carrier of or have active <strong>HEPATITIS B VIRUS</strong> (HBV) infection, Cimzia may increase the risk of reactivation in people who carry this virus. If this occurs, you should stop using Cimzia. Your doctor should test you for HBV before starting Cimzia.</p><p>&nbsp;</p><p><em>Heart failure</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have mild <strong>HEART FAILURE </strong>and you are being treated with Cimzia, your heart failure status must be closely monitored by your doctor. It is important to tell your doctor if you have had or have a serious heart condition. If you develop new or worsening symptoms of heart failure (e.g. shortness of breath or swelling of your feet), you must contact your doctor immediately. Your doctor may decide to stop treatment with Cimzia.</p><p>&nbsp;</p><p><em>Cancer</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is uncommon, but cases of certain types of <strong>CANCER</strong> have been reported in patients treated with Cimzia or other TNF blockers. People with more severe rheumatoid arthritis that have had the disease for a long time may have a higher than average risk of getting a kind of cancer that affects the lymph system, called lymphoma. If you take Cimzia, your risk of getting lymphoma or other cancers may increase. In addition, uncommon cases of non-melanoma skin cancer have been observed in patients taking Cimzia. If new skin lesions appear during or after therapy with Cimzia or existing skin lesions change appearance, tell your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There have been cases of cancers, including unusual types, in children and teenage patients taking TNF‑blocking agents, which sometimes resulted in death (see further down &ldquo;Children and adolescents&rdquo;).</p><p><em>&nbsp;</em></p><p><em>Other disorders</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with chronic obstructive pulmonary disease (COPD), or who are heavy smokers, may be at increased risk for cancer with Cimzia treatment. If you have COPD or are a heavy smoker, you should discuss with your doctor whether treatment with a TNF blocker is appropriate for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a nervous system disorder, such as multiple sclerosis, your doctor will decide whether you should use Cimzia.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In some patients the body may fail to produce enough of the blood cells that help your body fight infections or help you to stop bleeding. If you develop a fever that does not go away, bruise or bleed very easily or look very pale, call your doctor immediately. Your doctor may decide to stop treatment with Cimzia.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is uncommon, but symptoms of a disease called lupus (for example persistent rash, fever, joint pain and tiredness) may occur. If you experience these symptoms, contact your doctor. Your doctor may decide to stop treatment with Cimzia.</p><p>&nbsp;</p><p><em>Vaccinations</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor if you have had, or are due to have a vaccine. You should not receive certain (live) vaccines while using Cimzia.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain vaccinations may cause infections. If you received Cimzia while you were pregnant, your baby may be at higher risk for getting such an infection for up to approximately five months after the last dose you received during pregnancy. It is important that you tell your baby&#39;s doctors and other health care professionals about your Cimza use so they can decide when your baby should receive any vaccine.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Operations or dental procedures</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor if you are going to have any operations or dental procedures. Tell your surgeon or dentist performing the procedure that you are having treatment with Cimzia</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Cimzia is not recommended for use in children and adolescents under the age of 18 years.</p><p>&nbsp;</p><p><strong>Other medicines and Cimzia</strong></p><p>You should <strong>NOT</strong> take Cimzia if you are using the following medicines used to treat rheumatoid arthritis:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anakinra</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abatacept</p><p>If you have questions, please ask your doctor.</p><p>&nbsp;</p><p>Cimzia can be taken together with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methotrexate,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corticosteroids, or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain medicines including nonsteroidal anti-inflammatory medicines (also called NSAIDs).</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>There is limited experience with Cimzia in pregnant women.</p><p>Cimzia should be used during pregnancy only if clearly needed. If you are a woman of childbearing potential, discuss with your doctor regarding use of adequate contraception while using Cimzia. For women planning pregnancy, contraception may be considered for 5 months after the last Cimzia dose.</p><p>&nbsp;</p><p>If you received Cimzia during your pregnancy, your baby may have a higher risk for getting an infection. It is important that you tell your baby&rsquo;s doctors and other health care professionals about your Cimzia use before the baby receives any vaccine (for more information see section on vaccinations).</p><p>&nbsp;</p><p>Cimzia can be used during breastfeeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Cimzia may have a minor influence on your ability to drive and use machines. Dizziness (including room spinning sensation, blurred vision and tiredness) may occur after you take Cimzia.</p><p>&nbsp;</p><p><strong>Cimzia contains sodium acetate and sodium chloride</strong></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 400&nbsp;mg, i.e. essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Rheumatoid arthritis</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose for adults with rheumatoid arthritis is 400&nbsp;mg given at weeks&nbsp;0, 2 and 4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is followed by a maintenance dose of 200&nbsp;mg every 2 weeks. If you respond to the medicine, your doctor may prescribe an alternative maintenance dosing of 400&nbsp;mg every 4&nbsp;weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate is continued while using Cimzia. If your doctor determines that methotrexate is inappropriate, Cimzia can be given alone.</p><p>&nbsp;</p><p><strong>Axial spondyloarthritis</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose for adults with axial spondyloarthritis is 400&nbsp;mg given at weeks&nbsp;0, 2 and 4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is followed by a maintenance dose<strong> </strong>of 200&nbsp;mg every 2&nbsp;weeks (from week&nbsp;6) or 400&nbsp;mg every 4&nbsp;weeks (from week&nbsp;8) as instructed by your physician.</p><p>&nbsp;</p><p><strong>Psoriatic arthritis</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose for adults with psoriatic arthritis is 400&nbsp;mg given at weeks&nbsp;0, 2 and 4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is followed by a maintenance dose<strong> </strong>of 200&nbsp;mg every 2 weeks. If you respond to the medicine, your doctor may prescribe an alternative maintenance dosing of 400&nbsp;mg every 4&nbsp;weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate is continued while using Cimzia. If your doctor determines that methotrexate is inappropriate, Cimzia can be given alone.</p><p>&nbsp;</p><p><strong>Plaque psoriasis</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose for adults with plaque psoriasis is 400 mg every 2 weeks given at weeks&nbsp;0, 2 and 4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is followed by a maintenance dose<strong> </strong>of 200&nbsp;mg every 2 weeks, or 400&nbsp;mg every 2&nbsp;weeks as instructed by your physician.</p><p>&nbsp;</p><p><strong>How Cimzia is given</strong></p><p>Cimzia will usually be given to you by a specialist doctor or healthcare professional. You will be given Cimzia as either one (200&nbsp;mg dose) or two injections (400&nbsp;mg dose) under the skin (subcutaneous use, abbreviation: SC). It is usually injected into the thigh or tummy. However, do not inject in an area where the skin is reddened, bruised, or hard.</p><p>&nbsp;</p><p><strong>Instructions for self-injecting Cimzia</strong></p><p>After suitable training, your doctor may also allow you to inject Cimzia yourself. Please read the instructions at the end of this leaflet on how to inject Cimzia.</p><p>&nbsp;</p><p>If your doctor has allowed you to self-inject, you should follow up with your doctor before you continue to self-inject:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after 12 weeks if you have rheumatoid arthritis, axial spondyloarthritis or psoriatic arthritis, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after 16 weeks if you have plaque psoriasis.</p><p>This is so that the doctor can determine if Cimzia is working for you or if another treatment needs to be considered.</p><p>&nbsp;</p><p><strong>If you use more Cimzia than you should</strong></p><p>If your doctor has allowed you to self-inject and you accidentally inject Cimzia more frequently than prescribed, you should tell your doctor. Always take the outer carton from the Cimzia package with you, even if it is empty.</p><p>&nbsp;</p><p><strong>If you forget to use Cimzia</strong></p><p>If your doctor has allowed you to self-inject and you forget to give yourself an injection, you should inject the next dose of Cimzia as soon as you remember. Then, talk to your doctor and inject the following doses as instructed.</p><p>&nbsp;</p><p><strong>If you stop using Cimzia</strong></p><p>Do not stop using Cimzia without talking to your doctor first.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Tell your doctor <strong>IMMEDIATELY</strong> if you notice any of the following side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe rash, hives or other signs of allergic reaction (urticaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen face, hands, feet (angioedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble breathing, swallowing (multiple causes for these symptoms)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath with exertion or upon lying down or swelling of the feet (heart failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of blood disorders such as persistent fever, bruising, bleeding, paleness (pancytopaenia, anaemia, low platelet count, low white blood cell count)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious skin rashes. These can appear as reddish target-like macules or circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu-like symptoms. (Stevens-Johnson syndrome)</p><p>&nbsp;</p><p>Tell your doctor <strong>AS SOON AS POSSIBLE</strong> if you notice any of the following side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of infection such as fever, malaise, wounds, dental problems, burning on urination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak or tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arm or leg weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bump or open sore that doesn&#39;t heal</p><p>&nbsp;</p><p>The symptoms described above can be due to some of the side effects listed below, which have been observed with Cimzia:</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infections in any site (a collection of pus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral infections (including cold sores, shingles, and influenza)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash or itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headaches (including migraines)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensory abnormalities such as numbness, tingling, burning sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak and generally unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic conditions including allergic rhinitis and allergic reactions to the medicine (including anaphylactic shock)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibody directed against normal tissue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood and lymphatic system cancers like lymphoma and leukaemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; solid organ cancers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin cancers, pre-cancerous skin lesions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; benign (non-cancerous) tumours and cysts (including those of the skin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart problems including weakened heart muscle, heart failure, heart attack, chest discomfort or chest pressure, abnormal heart rhythm including irregular heart beats</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oedema (swelling in the face or legs)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lupus (immune/connective tissue disease) symptoms (joint pain, skin rashes, photosensitivity and fever)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the blood vessels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sepsis (serious infection which can result in organ failure, shock or death)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tuberculosis infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infections (occur when the ability to fight off infection is lessened)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory disorders and inflammation (including asthma, shortness of breath, cough, blocked sinuses, pleurisy, or difficulty breathing)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach problems including abdominal fluid collection, ulcers (including oral ulcers), perforation, distension, inflammation heartburn, upset, dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bile problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle problems including increased muscle enzymes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood levels of different salts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in cholesterol and fat levels in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots in the veins or lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding or bruising</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changed numbers of blood cells, including low red cell count (anaemia), low platelet counts, increased platelet counts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen lymph nodes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu-like symptoms, chills, altered temperature perception, night sweats, flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety and mood disorders such as depression, appetite disorders, weight change</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo (dizziness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling faint, including loss of consciousness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nerve disorders in the extremities including symptoms of numbness, tingling, burning sensation, dizziness, tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin disorders such as new onset or worsening of psoriasis, inflammation of the skin (such as eczema), sweat gland disorders, ulcers, photosensitivity, acne, hair loss, discoloration, nail separation, dry skin and injuries</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired healing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney and urinary problems including impairment of kidney function, blood in the urine and urinary disturbances</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; menstrual cycle (monthly period) disorders including lack of bleeding, or heavy or irregular bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye and eyelid inflammation, vision disturbances, problems with tears</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some blood parameters increased (blood alkaline phosphatase increased)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prolonged coagulation (clotting) test times</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal cancer, melanoma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung inflammation (interstitial lung disease, pneumonitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke, blockage in blood vessels (arteriosclerosis), poor blood circulation which makes the toes and fingers numb and pale (Raynaud&rsquo;s phenomenon), mottled purplish skin discoloration, small veins near the surface of the skin may become visible</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pericardial inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiac arrhythmia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlarged spleen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of red cell mass</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; white blood cell morphology abnormal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; formation of stones in the gall bladder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney problems (including nephritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immune disorders such as sarcoidosis (rash, joint pain, fever), serum sickness, inflammation of the fat tissue, angioneurotic oedema (swelling of the lips, face, throat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thyroid disorders (goitre, tiredness, weight loss)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased iron levels in the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood levels of uric acid</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicide attempt, mental impairment, delirium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the nerves for hearing, seeing, or of the face, impaired coordination or balance</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased gastrointestinal motility</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fistula (tract from one organ to another) (any site)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral disorders including&nbsp; pain on swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin sloughing, blistering, hair texture disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sexual dysfunction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-Johnson syndrome (a serious skin condition which early symptoms include malaise, fever, headache and rash)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammatory skin rash (erythema multiforme)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lichenoid reactions (itchy reddish-purple skin rash and/or threadlike white-grey lines on mucous membranes)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; multiple sclerosis*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guillain‑Barr&eacute; syndrome*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Merkel cell carcinoma (a type of skin cancer)*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaposi&rsquo;s sarcoma (a rare cancer related to infection with human herpes virus 8. Kaposi&rsquo;s sarcoma most commonly appears as purple lesions on the skin)</p><p>&nbsp;</p><p>&nbsp;</p><p>*These events have been related to this class of medicines but the incidence with Cimzia is not known.</p><p>&nbsp;</p><p><u>Other side effects</u></p><p>When Cimzia has been used to treat other diseases the following uncommon side effects have occurred:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal stenosis (narrowing of part of the digestive system).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal obstructions (blockages of the digestive system).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; general physical health deterioration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spontaneous abortion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; azoospermia (lack of sperm production).</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the pack and syringe after EXP.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C ‑ 8&deg;C).</p><p>Do not freeze.</p><p>Keep the pre-filled syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if the solution is discoloured, cloudy or if you can see particles in it.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&nbsp;</p><p><strong>What Cimzia contains </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is certolizumab pegol. Each pre-filled syringe contains 200&nbsp;mg of certolizumab pegol in one ml.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: sodium acetate, sodium chloride and water for injection (see &ldquo;Cimzia contains sodium acetate and sodium chloride&rdquo; in section 2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                		What Cimzia looks like and contents of the pack
	Cimzia is provided as a solution for injection in a ready to use pre-filled syringe. The solution is clear to opalescent, colourless to yellow.
	
	One Cimzia pack contains:
•	two pre-filled syringes of solution, and
•	two alcohol wipes (for cleansing the areas chosen for injection).
	
	Packs of 2 pre-filled syringes and 2 alcohol wipes .

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&nbsp;</p><p><strong>Marketing Authorisation Holder </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>UCB Pharma S.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>All&eacute;e de la Recherche 60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>B-1070 Bruxelles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Belgium&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p><strong>&nbsp;</strong></p><p>Vetter Pharma-Fertigung</p><p>GmbH &amp; Co. KG</p><p>Eisenbahnstrasse 2-4,</p><p>88085 Langenargen,</p><p>Germany</p><p><strong>&nbsp;</strong></p><p><strong>Batch released by</strong></p><p><strong>&nbsp;</strong></p><p>UCB Pharma S.A.</p><p>Chemin du Foriest</p><p>B-1420 Braine l&#39;Alleud</p><p>Belgium</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in {11/2020} 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي دواء سيمزيا على المادة الفعالة سيرتوليزوماب بيجول، وهي جزء من الأجسام المضادة البشرية. والأجسام المضادة هي بروتينات تعمل بشكل خاص على التعرف على البروتينات الأخرى والارتباط بها. يرتبط سيمزيا ببروتين معين يُسمى عامل النخر الورمي ألفا (TNF&alpha;). &nbsp;ومن ثم يحصر عقار سيمزيا عامل نخر الورم ألفا مما يحد من الأمراض الالتهابية مثل التهاب المفاصل الروماتويدي والتهاب المفاصل الفقارية المحورية والتهاب المفاصل الصدفي والصدفية. كما أن الأدوية التي ترتبط بعامل النخر الورمي ألفا تُسمى أيضًا مثبطات عامل النخر الورمي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم دواء سيمزيا في البالغين لـعلاج الأمراض الالتهابية التَّالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب المفاصل الروماتويدي.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب المفاصل الفقارية المحوري</strong> (بما في ذلك التهاب الفقار المقسط والتهاب المفاصل الفقارية المحوري دون وجود دليل في الأشعة يُشير إلى الإصابة بالتهاب الفقار المقسط).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب المفاصل الصدفي.</strong></p><ul><li dir="RTL"><strong>صدفية لويحية</strong></li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التهاب المفاصل الروماتويدي</strong></p><p dir="RTL">يُستخدم دواء سيمزيا لعلاج التهاب المفاصل الروماتويدي. التهاب المفاصل الروماتويدي هو مرض التهابي بالمفاصل. إذا كنت مصابًا بالتهاب مفاصل روماتويدي نشط بدرجة تتراوح بين المعتدل والشديد، فقد يتم إعطاؤك أدوية أخرى أولًا وعادة ما يكون ميثوتريكسات. إذا لم تستجب لتلك الأدوية بشكل كافٍ، فسيتم إعطاؤك دواء سيمزيا بمصاحبة ميثوتريكسات لعلاج التهاب المفاصل الروماتويدي لديك. إذا قرر طبيبك أن ميثوتريكسات غير مناسب، يمكن استخدام دواء سيمزيا بمفرده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كذلك يمكن استخدام دواء سيمزيا بمصاحبة ميثوتريكسات لعلاج التهاب المفاصل الروماتويدي الشديد النشط المُترقي دون استخدام مسبق لميثوتريكسات أو غيره من الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم دواء سيمزيا، الذي ستستخدمه بمصاحبة ميثوتريكسات، للأغراض التَّالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحد من علامات مرضك وأعراضه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبطاء التلف الذي يصيب غضاريف وعظام المفاصل نتيجة المرض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحسين الوظائف البدنية لديك وأداء المهام اليومية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التهاب الفقار المقسط والتهاب المفاصل الفقارية المحوري دون وجود دليل في الأشعة يُشير إلى الإصابة بالتهاب الفقار المقسط</strong></p><p dir="RTL">يُستخدم دواء سيمزيا في علاج التهاب الفقار المقسط والتهاب المفاصل الفقارية المحوري الشَّديدين النَّشطين دون وجود دليل في الأشعة يُشير إلى الإصابة بالتهاب الفقار المقسط (يُشار إليه أحيانًا بالتهاب المفاصل الفقارية المحوري غير الظَّاهر بالأشعة). تُعد هذه الأمراض من الأمراض الالتهابية للعمود الفقري. إذا كنت مصابًا بالتهاب الفقار المقسط أو التهاب المفاصل الفقارية المحوري غير الظَّاهر بالأشعة، فسيتم إعطاؤك أدوية أخرى أولًا. إذا لم تستجب لتلك الأدوية بشكل كافٍ، فسيتم إعطاؤك دواء سيمزيا للأغراض التَّالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحد من علامات مرضك وأعراضه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحسين الوظائف البدنية لديك وأداء المهام اليومية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التهاب المفاصل الصدفي</strong></p><p dir="RTL">يُستخدم دواء سيمزيا لعلاج التهاب المفاصل الصدفي النَّشط. التهاب المفاصل الصدفي هو مرض التهابي بالمفاصل، وعادة يصاحبه مرض الصدفية. إذا كنت مصابًا بالتهاب المفاصل الصدفي النَّشط، فسيتم إعطاؤك أدوية أخرى أولًا وعادة ما تكون ميثوتريكسات. إذا لم تستجب لتلك الأدوية بشكل كافٍ، فسيتم إعطاؤك دواء سيمزيا بمصاحبة ميثوتريكسات للأغراض التَّالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحد من علامات مرضك وأعراضه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحسين الوظائف البدنية لديك وأداء المهام اليومية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وفي حال إذا قرر طبيبك أن دواء ميثوتركسات غير ملائم، فيمكن إعطاء دواء سيمزيا وحده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الصدفية اللويحية</strong></p><p dir="RTL">يُستخدم عقار سيمزيا لعلاج الصدفية اللويحية المعتدلة إلى الشديدة. تُعد الصَّدفية اللويحية أحد الأمراض الالتهابية التي تصيب الجلد ويمكن أيضًا أن تصيب فروة الرَّأس والأظافر.</p><p dir="RTL">يُستخدم عقار سيمزيا للحد من الالتهابات الجلدية وغيرها من علامات وأعراض مرضك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تجنب استخدام سيمزيا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا <strong>بالحساسية</strong> (الحساسية المفرطة) تجاه مادة السيرتوليزوماب بيجول أو أي من المكونات الأخرى لهذا الدواء (مدرجة في القسم السادس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى شديدة، بما في ذلك مرض <strong>السُل النشط</strong> (الدرن) (TB).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>قصور في القلب</strong> متوسط إلى شديد. أبلغ الطبيب، إذا كنت قد عانيت أو تعاني من حالة مرضية خطيرة في القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ الطبيب قبل العلاج باستخدام دواء سيمزيا إذا كانت تنطبق عليك أي من الحالات التالية:</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>تفاعلات الحساسية</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>تفاعلات حساسية</strong>؛ مثل ضيق في الصدر أو أزيز أو دوار أو تورم أو طفح جلدي، فتوقف عن استخدام سيمزيا واتصل بالطبيب <strong>فورًا. </strong>قد تحدث بعض هذه التفاعلات بعد أول استخدام لدواء سيمزيا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصِبت من قبل بتفاعلات حساسية تجاه مادة اللاتكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>حالات العدوى</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من <strong>حالات عدوى متكررة أو انتهازية</strong> أو غيرها من الحالات المرضية التي تزيد من خطر الإصابة بالعدوى (مثل العلاج بمثبطات المناعة، وهي أدوية يمكنها أن تقلل من قدرتك على مكافحة العدوى).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى أو إذا ظهرت لديك أعراض مثل الحمى أو الجروح أو التعب أو مشكلات بالأسنان. إذ قد تصاب بالعدوى بسهولة أكثر أثناء علاجك بدواء سيمزيا، بما في ذلك حالات العدوى الخطيرة، أو في حالات نادرة، حالات العدوى التي تشكل تهديدًا على الحياة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم رصد حالات لمرض <strong>السُل</strong> <strong>(الدرن</strong>) <strong>(</strong><strong>TB</strong><strong>)</strong> لدى المرضى الذين تم علاجهم بدواء سيمزيا، وسيفحصك الطبيب للتحقق من علامات وأعراض مرض السُل قبل البدء في استعمال الدواء. ويشمل هذا الفحص التاريخ المرضي الشامل وأشعة سينية على الصدر واختبار التوبركولين. إذا تم تشخيص السُل الكامن (غير النشط)، فقد تحتاج إلى تلقي الأدوية المناسبة المضادة للسُل قبل البدء في استعمال سيمزيا. وفي حالات نادرة يمكن أن تُصاب بمرض السُّل خلال فترة العلاج حتى لو كنت قد تلقيت العلاج الوقائي لمرض السُّل. ومن الضروري للغاية أن تخبر الطبيب في حال إذا كنت قد عانيت مسبقًا من مرض السُل أو إذا كنت على اتصال وثيق بشخص كان مصابًا بالسُل. إذا ظهرت أعراض مرض السُل (سعال مستمر وفقدان الوزن وخمول وحمى خفيفة)، أو أي عدوى أخرى أثناء أو بعد العلاج بدواء سيمزيا، فأبلغ الطبيب على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت معرضًا لخطر الإصابة بعدوى <strong>فيروس الالتهاب الكبدي </strong><strong>B</strong> ( (HBVأو إذا كنت حاملاً له أو مصابًا بالالتهاب الكبدي B النشط، فقد يزيد دواء سيمزيا من خطر استنشاط العدوى لدى الأشخاص الحاملين للفيروس. في حال حدوث ذلك، يجب عليك التوقف عن استعمال سيمزيا. يجب أن يُجري لك الطبيب اختبار فيروس HBV قبل البدء في استعمال سيمزيا<strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><em>قصور القلب</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>قصور خفيف في القلب</strong> ويتم علاجك بدواء سيمزيا، فلابد من مراقبة وضع قصور القلب لديك عن كثب من قِبل الطبيب. ومن الضروري إبلاغ الطبيب إذا كنت قد عانيت أو تعاني من حالة مرضية خطيرة في القلب. إذا ظهرت لديك أعراض جديدة أو متفاقمة لقصور القلب (مثل حدوث ضيق في التنفس أو تورم القدمين)، فيتعين عليك الاتصال بالطبيب على الفور. وقد يقرر الطبيب إيقاف العلاج بدواء سيمزيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>السرطان</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وهو أمر غير شائع، ولكن تم رصد حالات لأنواع معينة من <strong>السرطان</strong> لدى المرضى الذين تم علاجهم بدواء سيمزيا أو غيره من مثبطات عامل النخر الورمي. إن الأشخاص الذين كانوا يعانون من مرض التهاب المفاصل الروماتويدي الشديد لفترة طويلة، قد يواجهون خطرًا أعلى من المتوسط للإصابة بنوع من مرض السرطان يؤثر على الجهاز اللمفاوي، يُسمى بالورم اللمفي. إذا كنت تتناول دواء سيمزيا، فقد يزيد لديك خطر الإصابة بالورم اللمفي أو أنواع أخرى من السرطان. فضلاً عن ذلك، لوحظت حالات غير شائعة من سرطان الجلد غير الميلانيني لدى المرضى الذين يتناولون دواء سيمزيا. إذا ظهرت إصابات جلدية جديدة أثناء أو بعد العلاج بدواء سيمزيا أو تغير مظهر الإصابات الجلدية الموجودة، فأبلغ الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم تسجيل حالات لمرض السرطان، بما في ذلك الأنواع غير العادية، في المرضى الأطفال والمراهقين الذين يتناولون عقاقير مثبطة لعامل النخر الورمي، والتي أدت في بعض الحالات إلى الوفاة (طالع المزيد من التفاصيل أدناه في قسم &quot;الأطفال والمراهقون&quot;).</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>اضطرابات أخرى</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;بالنسبة للمرضى المصابين بمرض الانسداد الرئوي المزمن (COPD) أو المدخنين بشراهة، قد يزيد لديهم خطر الإصابة بالسرطان عند العلاج بدواء سيمزيا. إذا كنت تعاني من مرض الانسداد الرئوي المزمن(COPD) أو كنت مدخنًا بشراهة، فينبغي عليك مراجعة الطبيب لمعرفة ما إذا كان العلاج بمثبط عامل النخر الورمي ملائمًا بالنسبة لك أم لا.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب في الجهاز العصبي؛ مثل التصلب المتعدد، فسيقرر طبيبك ما إذا كان يجب عليك استخدام دواء سيمزيا أم لا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في بعض المرضى؛ قد يفشل الجسم في إنتاج عدد كافٍ من خلايا الدم التي من شأنها مساعدة جسمك في مقاومة العدوى أو مساعدتك على وقف النزيف. إذا أصبت بحمى بشكل مستمر أو كدمة أو إذا كنت تتعرض للنزيف بسهولة كبيرة أو تبدو شاحبًا للغاية، فاتصل بالطبيب على الفور. وقد يقرر الطبيب إيقاف العلاج بدواء سيمزيا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنه من غير الشائع، ولكن قد تحدث أعراض مرض يُسمى الذِّئبة (على سبيل المثال، الطفح الجلدي المستمر والحمى وآلام المفاصل والتعب). إذا شعرت بهذه الأعراض، فاتصل بالطبيب. وقد يقرر الطبيب إيقاف العلاج بدواء سيمزيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>اللقاحات</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث إلى طبيبك إذا كنت قد أخذت أحد اللقاحات أو مقبلاً على أخذه. إذ أنه لا يجب عليك أخذ بعض اللقاحات (الحية) أثناء استخدام دواء سيمزيا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقد تتسبب بعض اللقاحات في الإصابة بحالات عدوى. إذا تلقيتِ دواء سيمزيا خلال فترة الحمل، فقد يكون طفلك أكثر عرضة للإصابة بمثل هذه العدوى لمدة تصل إلى حوالي خمسة أشهر بعد آخر جرعة تلقيتيها أثناء الحمل. ومن الضروري إبلاغ أطباء طفلك وغيرهم من متخصصي الرعاية الصحية بشأن استعمالك لدواء سيمزيا حتى يتمكنوا من تحديد متى ينبغي أن يتلقى طفلك أي لقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>العمليات أو إجراءات الأسنان</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث إلى طبيبك إذا كنت ستخضع لأية عمليات أو إجراءات تتعلق بالأسنان. أبلغ الجراح أو طبيب الأسنان الذي سيقوم بالإجراء أنك تتلقى علاجًا بدواء سيمزيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُوصى باستخدام سيمزيا مع الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استعمال الأدوية الأخرى مع دواء سيمزيا</strong></p><p dir="RTL">ينبغي عليك <strong>عدم</strong> تناول دواء سيمزيا إذا كنت تستعمل الأدوية التالية التي تستخدم لعلاج التهاب المفاصل الروماتويدي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أناكينرا (anakinra)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أباتاسيبت (abatacept)</p><p dir="RTL">إذا كانت لديك أية أسئلة، فيُرجى استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن تناول سيمزيا مع الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميثوتركسات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات أو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تخفيف الألم؛ بما فيها مضادات الالتهاب اللاسترويدية (التي تُسمى أيضًا NSAIDs).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ الطبيب أو الصيدلي إذا كنت تتناول أي أدوية أخرى أو تناولتها مؤخرًا أو قد تتناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة أو تظنين أنكِ حامل أو تخططين لإنجاب طفل، فاستشيري الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولتِ سيمزيا أثناء فترة الحمل، فقد يكون طفلك أكثر عرضة للإصابة بالعدوى. ومن الضروري إبلاغ أطباء طفلك وغيرهم من متخصصي الرعاية الصحية بشأن استعمالك لدواء سيمزيا قبل أن يتلقى الطفل أي لقاح (للمزيد من المعلومات، راجعي قسم اللقاحات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استعمال دواء سيمزيا أثناء الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الماكينات</strong></p><p dir="RTL">قد يكون لدواء سيمزيا تأثير بسيط على قدرتك على القيادة واستخدام الماكينات. وقد يحدث دوار (بما في ذلك الإحساس بدوران الغرفة وعدم وضوح الرؤية والتعب) بعد تناول دواء سيمزيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي سيمزيا على أسيتات الصوديوم وكلوريد الصوديوم</strong></p><p dir="RTL">يحتوي هذا المنتج الطبي على أقل من 1 مليمول من الصوديوم (23 ملجم) لكل 400 ملجم، أي أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">يجب دومًا استخدام هذا الدواء حسب إرشادات الطبيب أو الصيدلي على نحو دقيق. كما يجب الرجوع إلى الطبيب أو الصيدلي في حالة وجود أي أمور غير واضحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التهاب المفاصل الروماتويدي</strong></p><ul><li dir="RTL">تبلغ الجرعة المبدئية للبالغين المصابين بالتهاب المفاصل الروماتويدي 400 ملجم، يتم إعطاؤها في الأسبوع 0<strong> </strong>والثاني والرابع.</li><li dir="RTL">وتتبعها جرعة مداومة تبلغ 200 ملجم كل أسبوعين. وفي حالة استجابتك للدواء، قد يصف لك الطبيب جرعة مداومة بديلة تبلغ 400 ملجم كل 4 أسابيع.</li><li dir="RTL">يستمر العلاج بالميثوتركسات أثناء استخدام سيمزيا. وفي حال إذا قرر طبيبك أن دواء ميثوتركسات غير ملائم، فيمكن إعطاء دواء سيمزيا وحده.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التهاب المفاصل الفقارية المحوري</strong></p><ul><li dir="RTL">تبلغ <strong>ا</strong>لجرعة المبدئية للبالغين الذين يعانون من التهاب المفاصل الفقارية المحوري 400 ملجم يتم إعطاؤها في الأسبوع 0 والثاني والرابع.</li><li dir="RTL">&nbsp;ويلي ذلك جرعة مداومة<strong> </strong>تبلغ 200 ملجم كل أسبوعين (بدءًا من الأسبوع السادس)، أو 400 ملجم كل 4 أسابيع (بدءًا من الأسبوع الثامن) وفق إرشادات الطبيب المعالج لك.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التهاب المفاصل الصدفي</strong></p><ul><li dir="RTL">تبلغ الجرعة المبدئية للبالغين الذين يعانون من التهاب المفاصل الصدفي 400 ملجم يتم إعطاؤها في الأسبوع 0 والثاني والرابع.</li><li dir="RTL">ويلي ذلك جرعة مداومة تبلغ 200 ملجم كل أسبوعين. وقد يصف لك الطبيب، في حالة استجابتك للدواء، جرعة مداومة بديلة تبلغ 400 ملجم كل 4 أسابيع.</li><li dir="RTL">&nbsp;ويستمر العلاج بالميثوتركسات أثناء استخدام سيمزيا. وإذا ما قرر طبيبك أن دواء ميثوتركسات غير ملائم، فيمكن إعطاء دواء سيمزيا وحده.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الصدفية اللويحية</strong></p><ul><li dir="RTL">تبلغ جرعة البدء للبالغين المصابين بالصدفية اللويحية 400 مجم كل أسبوعين ويتم إعطاؤها في الأسابيع 0 و 2 و 4.</li><li dir="RTL">وتتبعها جرعة المداومة والتي تبلغ 200 مجم كل أسبوعين أو 400 مجم كل أسبوعين وفقًا لتعليمات طبيبك.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية إعطاء عقار سيمزيا</strong></p><p dir="RTL">عادةً ما يتم إعطاء دواء سيمزيا من قِبل طبيب متخصص أو أخصائي الرعاية الصحية. وسيتم إعطاؤك دواء سيمزيا إما كحقنة واحدة (جرعة مكونة من 200 ملجم) أو حقنتين (جرعة مكونة من 400 ملجم) تحت الجلد (للاستخدام تحت الجلد). وعادةً ما يتم حقنها في الفخذ أو البطن. مع ذلك، ينبغي عدم حقنه في المناطق حيث الجلد متصلب أو به احمرار أو كدمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>تعليمات حقن عقار سيمزيا ذاتيًّا</strong></p><p dir="RTL">بعد تلقي التدريب المناسب، قد يسمح لك الطبيب أيضًا بأخذ حقن سيمزيا بنفسك. يُرجى قراءة الإرشادات في نهاية هذه النشرة عن كيفية حقن دواء سيمزيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا سمح لك طبيبك بالحقن ذاتيًّا، ينبغي عليك استشارة طبيبك قبل مواصلة الحقن ذاتيًّا:</p><ul><li dir="RTL">بعد 12 أسبوعًا إذا كنت مُصابًا بالتهاب المفاصل الروماتويدي أو التهاب المفاصل الفقارية المحورية أو التهاب المفاصل الصدفي أو</li><li dir="RTL">بعد 16 أسبوعًا إذا كنت مُصابًا بالصدفية اللويحية.</li></ul><p dir="RTL">لكي يستطيع طبيبك تحديد ما إذا كان عقار سيمزيا فعالًا معك أو ما إذا كان من الضَّروري الأخذ بالاعتبار علاج آخر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما يجب فعله عند تناول جرعة زائدة من دواء سيمزيا</strong></p><p dir="RTL">إذا سمح لك الطبيب بالحقن الذاتي وقمت عن طريق الخطأ بحقن جرعة زائدة من دواء سيمزيا أكثر من الجرعة الموصوفة، فينبغي عليك إبلاغ الطبيب. احرص دائمًا على أخذ العلبة الخارجية لعبوة دواء سيمزيا معك، حتى وإن كانت فارغة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله عند نسيان استعمال سيمزيا</strong></p><p dir="RTL">إذا سمح لك الطبيب بالحقن الذاتي ونسيت إعطاء حقنة الدواء لنفسك، فينبغي عليك حقن الجرعة التالية من دواء سيمزيا حالما تتذكر.ثم تحدث مع طبيبك وقم بحقن &nbsp;الجرعات التالية &nbsp;وفقًا للتعليمات.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله عند التوقف عن استعمال سيمزيا</strong></p><p dir="RTL">لا تتوقف عن استعمال سيمزيا دون الرجوع إلى الطبيب أولاً.</p><p dir="RTL">إذا كانت لديك أية أسئلة أخرى عن استعمال هذا الدواء، فاستشر الطبيب أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث آثار جانبية على الرغم من عدم حدوث تلك الآثار الجانبية لكل من يتناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ الطبيب <strong>فورًا </strong>إذا لاحظت ظهور أي من الآثار الجانبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي شديد أو شرى أو علامات أخرى لتفاعلات الحساسية (الأرتكاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه واليدين والقدمين (الوذمة الوعائية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في التنفس والبلع (أسباب متعددة لهذه الأعراض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس عند بذل مجهود أو عند الاستلقاء أو تورم القدمين (قصور القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض اضطرابات الدم مثل الحمى المستمرة وظهور الكدمات والنزيف والشحوب (قلة الكريات الشاملة وفقر الدم وانخفاض عدد الصفائح الدموية وانخفاض عدد خلايا الدم البيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي خطير. قد يظهر على هيئة بقع حمراء شبيهة بالأهداف أو بقع دائرية تظهر غالبًا مع بثور مركزية في الجزع، وتقشُّر الجلد، وقرح بالفم والحَلْق والأنف والأعضاء التَّناسلية والعينين، ويمكن أن تُسبق بحمى وأعراض شبيهة بأعراض الأنفلونزا. (متلازمة ستيفنز- جونسون)</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ الطبيب <strong>في أسرع وقت ممكن</strong> إذا لاحظت ظهور أي من الآثار الجانبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات الإصابة بعدوى مثل الحمى والتوعك والجروح ومشكلات الأسنان وحرقان أثناء التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف أو التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النخز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اخدرار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواج الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الذراعين أو الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كدمة أو قرحة مفتوحة لا تلتئم</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تحدث الأعراض الموضحة أعلاه نتيجة لبعض الآثار الجانبية الواردة أدناه، والتي تمت ملاحظتها مع استعمال دواء سيمزيا:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار شائعة (قد تؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>10</strong><strong> أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى البكتيرية في أي موضع (وهي تجمع صديدي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى الفيروسية (بما في ذلك القروح الباردة والهربس النطاقي والأنفلونزا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو حكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع (بما في ذلك الصداع النصفي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاختلالات الحسية؛ مثل الاخدرار والنخز والإحساس بالحرقان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف والتوعك بشكل عام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات بالكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تفاعلات في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من بين كل</strong> <strong>100</strong> <strong>شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات الحساسية بما فيها التهاب الأنف التحسسي وتفاعلات الحساسية تجاه الدواء (بما في ذلك صدمة الحساسية المفرطة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جسم مضاد موجه ضد الأنسجة الطبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدم والجهاز الليمفاوي مثل الورم اللمفي وابيضاض الدم (اللوكيميا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطانات الأعضاء الصلبة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطانات الجلد، وإصابات جلدية محتملة التسرطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأورام الحميدة (غير السرطانية) والتكيسات (بما في ذلك الكيسات الجلدية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات القلب؛ بما في ذلك ضعف عضلة القلب وقصور القلب والتعرض لنوبة قلبية وضيق في الصدر أو ضغط في الصدر واضطرابات في إيقاع القلب بما في ذلك عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوذمة (تورم في الوجه أو الساقين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض الذئبة (أمراض المناعة/النسيج الضام) وهي (آلام المفاصل والطفح الجلدي والحساسية تجاه الضوء والحمى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنتان (عدوى خطيرة يمكن أن تؤدي إلى فشل العضو أو صدمته أو موته)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى السُل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية (تحدث عندما تقل القدرة على محاربة العدوى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات والتهابات الجهاز التنفسي (بما في ذلك الربو أو ضيق في التنفس أو السُعال أو انسداد الجيوب أو التهاب الغشاء المحيط بالرئتين أو صعوبة التنفس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في المعدة بما في ذلك تجمع السوائل في البطن والقرح (بما فيها قرح الفم) والانثقاب والانتفاخ والتهاب المعدة وحرقة في المعدة وألم وجفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات الصفراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات العضلات؛ بما فيها زيادة إنزيمات العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في مستويات الدم للأملاح المختلفة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في مستويات الكوليسترول والدهون في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلطات الدموية في الأوردة أو الرئتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف أو التكدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير عدد خلايا الدم بما في ذلك انخفاض عدد خلايا الدم الحمراء (فقر الدم) أو انخفاض عدد الصفائح الدموية أو زيادة عدد الصفائح الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم العقد الليمفاوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مشابهة لأعراض الإنفلوانزا والقشعريرة وتغير إدراك درجة الحرارة والتعرق الليلي والبيغ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق والاضطرابات المزاجية مثل الاكتئاب واضطرابات الشهية وتغير الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين في الأذنين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة (دوار)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بدوار، بما في ذلك فقدان الوعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأعصاب في الأطراف؛ بما في ذلك أعراض الاخدرار والنخز والإحساس بحرقان والدوخة والرعشة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الجلد مثل بداية ظهور مرض الصدفية أو تفاقمه والتهاب الجلد (مثل الإكزيما) واضطرابات الغدد العَرقية والقرح والحساسية تجاه الضوء وحَب الشباب وتساقط الشعر وتغير لون الجلد وتشقق الأظافر وجفاف الجلد والإصابات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف التئام الجروح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات بالكلى والبول؛ بما في ذلك قصور وظائف الكلى ووجود دم في البول واضطرابات البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات دورة الحيض (الدورة الشهرية) بما في ذلك قلة النزيف أو النزيف الحاد أو غير المنتظم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الثدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين والجفن واضطرابات الرؤية ومشكلات تتعلق بالدموع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة بعض مؤشرات الدم (ارتفاع الفوسفاتيز القلوي في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في قيم اختبار الوقت اللازم للتخثر (التجلط)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار نادرة (قد تؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>1000</strong><strong> شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجهاز الهضمي والورم الميلانيني</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئة (مرض الرئة الخلالي، الالتهاب الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية وانسداد الأوعية الدموية (تصلب الشرايين) وضعف الدورة الدموية مما يصيب أصابع القدمين والأصابع بالاخدرار والشحوب (ظاهرة رينود)، وتلون الجلد باللون الأرجواني النقطي، كما يمكن أن تصبح الأوردة الصغيرة القريبة من سطح الجلد مرئية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب تأموري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الطحال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة كتلة الخلايا الحمراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شذوذ في تشكيل خلايا الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكون حصوات في المرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكلى (بما فيها التهاب الكلية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات المناعة مثل الساركويد (الطفح الجلدي وآلام المفاصل والحمى) وداء المصل والتهاب الأنسجة الدهنية والوذمة الوعائية العصبية (تورم الشفتين والوجه والحلق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الغدة الدرقية (تضخم الغدة الدرقية والتعب وفقدان الوزن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات الحديد في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستويات حمض اليوريك في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محاولة الانتحار والإعاقة العقلية والهذيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أعصاب السمع أو الرؤية أو الوجه، وضعف التنسيق أو التوازن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حركة المعدة والأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الناسور (ممر من عضو إلى آخر) (في أي موضع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الفم؛ بما فيها الألم عند البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخشر الجلد وظهور تقرحات واضطراب في بنية الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل الوظائف الجنسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث نوبات&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم حالة تُدعى التهاب الجلد والعضلات (تبدو كطفح جلدي يصاحب ضعف العضلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفنز جونسون (حالة جلدية خطيرة تتضمن أعراضها الأولية تَوَعُّكًا، وحمى، وصداعًا وطفحًا جلديًّا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي التهابي (احمرار متعدد الأشكال).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حزازانية (طفح جلدي بنفسجي مائل للاحمرار مع حكة و/أو خطوط رمادية وبيضاء خيطية الشَّكل على الأغشية المخاطية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>معروفة (لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تواترها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>خلال</strong><strong> </strong><strong>الدراسات</strong><strong> </strong><strong>المتاحة):</strong></p><ul><li dir="RTL">التصلب المتعدد*</li><li dir="RTL">مُتَلاَزِمَةُ غيلان - باريه (التهاب الجذور والأعصاب الحاد)*</li><li dir="RTL">سرطان خلايا ميركل (أحد أنواع سرطان الجلد) *</li><li dir="RTL">ساركوما كابوزي (مرض سرطاني نادر يرتبط بالإصابة بعدوى فيروس الهربس البشري 8. تظهر ساركوما كابوزي في الغالب على شكل إصابات أرجوانية على الجلد)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">*ثبت أن هذه الأحداث تتعلق بهذه الفئة من الأدوية إلا أن إمكانية حدوثها مع دواء سيمزيا غير معروف.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>الآثار الجانبية الأخرى</u></p><p dir="RTL">عندما تم استخدام سيمزيا لعلاج أمراض أخرى، ظهرت الآثار الجانبية غير الشائعة التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضيُّق المعدة والأمعاء (ضيق جزء من الجهاز الهضمي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد المعدة والأمعاء (انسداد الجهاز الهضمي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور الصحة البدنية العامة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإجهاض التلقائي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقد النطاف (نقص إنتاج السائل المنوي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أصبت بأي من الآثار الجانبية، فيُرجى إبلاغ الطبيب أو الصيدلي أو الممرضة. ويشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العبوة والمحقنة بعد كلمة EXP.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزن في الثلاجة (ما بين 2 درجة مئوية إلى 8 درجات مئوية).</p><p dir="RTL">ولا يتم تجميده.</p><p dir="RTL">تُحفظ المحقنة المعبأة مسبقًا في علبة الكرتون الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا تغير لون المحلول أو كان غير رائق أو تمكنت من رؤية جزئيات فيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أية أدوية عن طريق مياه الصرف أو المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تُستخدم. إذ تساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>محتويات سيمزيا </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي سيرتوليزوماب بيجول. تحتوي كل محقنة معبأة مسبقًا على 200 ملجم من مادة سيرتوليزوماب بيجول في واحد ملليلتر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أما المكونات الأخرى فهي: أسيتات الصوديوم وكلوريد الصوديوم وماء معد للحقن (راجع &quot;يحتوي سيمزيا على أسيتات الصوديوم وكلوريد الصوديوم&quot; في القسم الثاني).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شكل دواء سيمزيا ومحتويات العبوة</strong></p><p dir="RTL">يتم توفير دواء سيمزيا في صورة محلول للحقن بداخل محقنة معبأة مسبقًا وجاهزة للاستخدام. ويكون المحلول صافيًا مائلاً إلى النقاء وعديم اللون مائلاً إلى الأصفر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي عبوة سيمزيا الواحدة على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 محقنة معبأة مسبقًا بالمحلول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 منديل مبلل بالكحول (لتطهير المناطق المختارة للحقن)</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر في عبوة تحتوي على 2 محقنة<strong> </strong>معبأة مسبقًا و2 منديل مبلل بالكحول</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق:</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp; </strong></p><p dir="RTL">UCB Pharma SA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">All&eacute;e de la Recherche 60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">B-1070 Bruxelles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">Belgium (بلجيكا)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة</strong><strong> </strong><strong>المصنعة</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">Vetter Pharma-Fertigung</p><p dir="RTL">GmbH &amp; Co. KG</p><p dir="RTL">Eisenbahnstrasse 2-4,</p><p dir="RTL">88085 Langenargen,</p><p dir="RTL">Germany</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>Batch released by:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">UCB Pharma S.A</p><p dir="RTL">Chemin du Foriest</p><p dir="RTL">B-1420 Braine l&#39;Alleud,</p><p dir="RTL">Belgium</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	آخر مراجعة لهذه النشرة تمت في {2020/11} 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cimzia 200 mg solution for injection in pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre-filled syringe contains 200 mg certolizumab pegol in one ml.

Certolizumab pegol is a recombinant, humanised antibody Fab' fragment against tumour necrosis factor alpha (TNFα) expressed in Escherichia coli and conjugated to polyethylene glycol (PEG).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

Clear to opalescent, colourless to yellow solution. The pH of the solution is approximately 4.7.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Rheumatoid arthritis</u></em></p><p>Cimzia, in combination with methotrexate (MTX), is indicated for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.</p><p>&nbsp;</p><p>Cimzia has been shown to reduce the rate of progression of joint damage as measured by<br />X‑ray and to improve physical function, when given in combination with MTX.</p><p>&nbsp;</p><p><em><u>Axial spondyloarthritis</u></em></p><p>Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:</p><p>&nbsp;</p><p><em>Ankylosing spondylitis (AS) (also known as radiographic axial spondyloarthritis)</em></p><p>Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).</p><p>&nbsp;</p><p><em>Axial spondyloarthritis without radiographic evidence of AS (also known as non-radiographic axial spondyloarthritis)</em></p><p>Adults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C‑reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs.</p><p>&nbsp;</p><p><em><u>Psoriatic arthritis </u></em></p><p>Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.</p><p>&nbsp;</p><p>Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.</p><p>&nbsp;</p><p><em><u>Plaque psoriasis</u></em></p><p>Cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.</p><p>&nbsp;</p><p>For details on therapeutic effects, see section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of conditions for which Cimzia is indicated. Patients should be given the special reminder card.</p><p>&nbsp;</p><p><u>Posology</u></p><p><em>&nbsp;</em></p><p><u>Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis</u></p><p><em>&nbsp;</em></p><p><em><u>Loading dose </u></em></p><p>The recommended starting dose of Cimzia for adult patients is 400&nbsp;mg (given as 2 subcutaneous&nbsp;injections of 200&nbsp;mg each) at weeks&nbsp;0, 2 and 4. For rheumatoid arthritis and psoriatic arthritis, MTX should be continued during treatment with Cimzia where appropriate.</p><p>&nbsp;</p><p><em><u>Maintenance dose</u></em></p><p><em>Rheumatoid arthritis</em></p><p>After the starting dose, the recommended maintenance dose of Cimzia for adult patients with rheumatoid arthritis is 200&nbsp;mg every 2&nbsp;weeks. Once clinical response is confirmed, an alternative maintenance dosing of 400&nbsp;mg every 4&nbsp;weeks can be considered. MTX should be continued during treatment with Cimzia where appropriate.</p><p>&nbsp;</p><p><em>Axial spondyloarthritis</em></p><p>After the starting dose, the recommended maintenance dose of Cimzia for adult patients with axial spondyloarthritis is 200&nbsp;mg every 2&nbsp;weeks or 400&nbsp;mg every 4&nbsp;weeks.</p><p>&nbsp;</p><p><em>Psoriatic arthritis</em></p><p>After the starting dose, the recommended maintenance dose of Cimzia for adult patients with psoriatic arthritis is 200&nbsp;mg every 2&nbsp;weeks. Once clinical response is confirmed, an alternative maintenance dosing of 400&nbsp;mg every 4&nbsp;weeks can be considered. MTX should be continued during treatment with Cimzia where appropriate.</p><p>&nbsp;</p><p>For the above indications, available data suggest that clinical response is usually achieved within 12&nbsp;weeks of treatment. Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit within the first 12&nbsp;weeks of treatment.</p><p>&nbsp;</p><p><em>Plaque psoriasis</em></p><p>After the starting dose, the maintenance dose of Cimzia for adult patients with plaque psoriasis is 200 mg every 2 weeks. A dose of 400 mg every 2 weeks can be considered in patients with insufficient response (see section 5.1).</p><p>Available data in adults with plaque psoriasis suggest that a clinical response is usually achieved within 16 weeks of treatment. Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit within the first 16&nbsp;weeks of treatment. Some patients with an initial partial response may subsequently improve with continued treatment beyond 16 weeks.</p><p>&nbsp;</p><p><em><u>Missed dose</u></em></p><p>Patients who miss a dose should be advised to inject the next dose of Cimzia as soon as they remember and then continue injecting subsequent doses as instructed.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Paediatric population (&lt;&nbsp;18&nbsp;years old)</em></p><p>The safety and efficacy of Cimzia in children and adolescents below age 18 years have not yet been established. No data are available.</p><p>&nbsp;</p><p><em>Elderly patients (&ge;&nbsp;65&nbsp;years old)</em></p><p>No dose adjustment is required. Population pharmacokinetic analyses showed no effect of age (see section 5.2).</p><p>&nbsp;</p><p><em>Renal and hepatic impairment</em></p><p>Cimzia has not been studied in these patient populations. No dose recommendations can be made (see section 5.2).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>The total content (1&nbsp;ml) of the pre-filled syringe should be administered as a subcutaneous injection only. Suitable sites for injection would include the thigh or abdomen.</p><p>&nbsp;</p><p>After proper training in injection technique, patients may self-inject using the pre-filled syringe if their physician determines that it is appropriate and with medical follow-up as necessary. The pre-filled syringe with needle guard should only be used by healthcare professionals. The physician should discuss with the patient which injection presentation option is the most appropriate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active tuberculosis or other severe infections such as sepsis or opportunistic infections (see section 4.4).

Moderate to severe heart failure (NYHA classes III/IV) (see section 4.4).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Traceability </u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><u>&nbsp;</u></p><p><u>Infections</u></p><p>Patients must be monitored closely for signs and symptoms of infections including tuberculosis before, during and after treatment with Cimzia. Because the elimination of certolizumab pegol may take up to 5&nbsp;months, monitoring should be continued throughout this period (see section 4.3).</p><p>&nbsp;</p><p>Treatment with Cimzia must not be initiated in patients with a clinically important active infection, including chronic or localised infections, until the infection is controlled (see section 4.3).</p><p>&nbsp;</p><p>Patients who develop a new infection while undergoing treatment with Cimzia should be monitored closely. Administration of Cimzia should be discontinued if a patient develops a new serious infection until the infection is controlled. Physicians should exercise caution when considering the use of Cimzia in patients with a history of recurring or opportunistic infection or with underlying conditions which may predispose patients to infections, including the use of concomitant immunosuppressive medications.</p><p>&nbsp;</p><p>Patients with rheumatoid arthritis may not manifest typical symptoms of infection, including fever, due to their disease and concomitant medicinal products. Therefore, early detection of any infection, particularly atypical clinical presentations of a serious infection, is critical to minimise delays in diagnosis and initiation of treatment.</p><p>&nbsp;</p><p>Serious infections, including sepsis and tuberculosis (including miliary, disseminated and extrapulmonary disease), and opportunistic infections (e.g. histoplasmosis, nocardia, candidiasis) have been reported in patients receiving Cimzia. Some of these events have been fatal.</p><p>&nbsp;</p><p><u>Tuberculosis</u></p><p>Before initiation of therapy with Cimzia, all patients must be evaluated for both active or inactive (latent) tuberculosis infection. This evaluation should include a detailed medical history for patients with a personal history of tuberculosis, with possible previous exposure to others with active tuberculosis, and with previous and/or current use of immunosuppressive therapy. Appropriate screening tests, e.g. tuberculin skin test and chest X‑ray, should be performed in all patients (local recommendations may apply). It is recommended that the conduct of these tests should be recorded in the patient&#39;s reminder card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.</p><p>&nbsp;</p><p>If active tuberculosis is diagnosed prior to or during treatment, Cimzia therapy must not be initiated and must be discontinued (see section 4.3).</p><p>&nbsp;</p><p>If inactive (&lsquo;latent&rsquo;) tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted. In all situations described below, the benefit/risk balance of Cimzia therapy should be very carefully considered.</p><p>&nbsp;</p><p>If latent tuberculosis is diagnosed, appropriate anti-tuberculosis therapy must be started before initiating treatment with Cimzia and in accordance with local recommendations.</p><p>Use of anti-tuberculosis therapy should also be considered before the initiation of Cimzia in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and in patients who have significant risk factors for tuberculosis despite a negative test for latent tuberculosis. Biological tests for tuberculosis screening should be considered before starting Cimzia treatment if there is any potential latent tuberculosis infection, regardless of BCG vaccination.</p><p>&nbsp;</p><p>Despite previous or concomitant prophylactic treatment for tuberculosis, cases of active tuberculosis have occurred in patients treated with TNF-antagonists including Cimzia. Some patients who have been successfully treated for active tuberculosis have redeveloped tuberculosis while being treated with Cimzia.</p><p>&nbsp;</p><p>Patients should be instructed to seek medical advice if signs/symptoms (e.g. persistent cough, wasting/weight loss, low grade fever, listlessness) suggestive of a tuberculosis infection occur during or after therapy with Cimzia.</p><p>&nbsp;</p><p><u>Hepatitis B virus (HBV) reactivation</u></p><p>Reactivation of hepatitis B has occurred in patients receiving a TNF‑antagonist including certolizumab pegol, who are chronic carriers of this virus (i.e., surface antigen positive). Some cases have had a fatal outcome.</p><p>&nbsp;</p><p>Patients should be tested for HBV infection before initiating treatment with Cimzia. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended.</p><p>&nbsp;</p><p>Carriers of HBV who require treatment with Cimzia should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy. Adequate data of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF‑antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV reactivation, Cimzia should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</p><p>&nbsp;</p><p><u>Malignancies and lymphoproliferative disorders</u></p><p>The potential role of TNF‑antagonist therapy in the development of malignancies is not known. Caution should be exercised when considering TNF‑antagonist therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop malignancy.</p><p>&nbsp;</p><p>With the current knowledge, a possible risk for the development of lymphomas, leukaemia or other malignancies in patients treated with a TNF‑antagonist cannot be excluded.</p><p>&nbsp;</p><p>In clinical trials with Cimzia and other TNF‑antagonists, more cases of lymphoma and other malignancies have been reported among patients receiving TNF‑antagonists than in control patients receiving placebo (see section 4.8). In the post marketing setting, cases of leukaemia have been reported in patients treated with a TNF‑antagonist. There is an increased background risk for lymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates the risk estimation.</p><p>&nbsp;</p><p>No trials have been conducted that include patients with a history of malignancy, or that continue treatment in patients who develop malignancy, while receiving Cimzia.</p><p>&nbsp;</p><p><em>Skin cancers</em></p><p>Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF‑antagonists including certolizumab pegol (see section 4.8). Periodic skin examination is recommended, particularly for patients with risk factors for skin cancer.</p><p>&nbsp;</p><p><em>Paediatric malignancy</em></p><p>Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22&nbsp;years of age) treated with TNF‑antagonists (initiation of therapy &le;&nbsp;18&nbsp;years of age) in the post marketing setting. Approximately half the cases were lymphomas. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression. A risk for the development of malignancies in children and adolescents treated with TNF‑antagonists cannot be excluded.</p><p>&nbsp;</p><p>Post‑marketing cases of hepatosplenic T-cell lymphoma (HSTCL), have been reported in patients treated with TNF‑antagonists. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. The majority of reported TNF‑antagonist cases occurred in adolescent and young adult males with Crohn&rsquo;s disease or ulcerative colitis. Almost all of these patients had received treatment with the immunosuppressants azathioprine and/or 6-mercaptopurine concomitantly with a TNF‑antagonist at or prior to diagnosis. A risk for development of hepatosplenic T-cell lymphoma in patients treated with Cimzia cannot be excluded.</p><p><u>&nbsp;</u></p><p><u>Chronic obstructive pulmonary disease (COPD)</u></p><p>In an exploratory clinical trial evaluating the use of another TNF‑antagonist, infliximab, in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung or head and neck, were report</p><p>&nbsp;</p><p>&nbsp;</p><p>ed in infliximab-treated patients compared with control patients. All patients had a history of heavy smoking. Therefore, caution should be exercised when using any TNF‑antagonist in COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</p><p>&nbsp;</p><p><u>Congestive heart failure</u></p><p>Cimzia is contraindicated in moderate or severe heart failure (see section 4.3). In a clinical trial with another TNF‑antagonist, worsening congestive heart failure and increased mortality due to congestive heart failure have been observed. Cases of congestive heart failure have also been reported in rheumatoid arthritis patients receiving Cimzia. Cimzia should be used with caution in patients with mild heart failure (NYHA class I/II). Treatment with Cimzia must be discontinued in patients who develop new or worsening symptoms of congestive heart failure.</p><p>&nbsp;</p><p><u>Haematological reactions</u></p><p>Reports of pancytopaenia, including aplastic anaemia, have been rare with TNF‑antagonists. Adverse reactions of the haematologic system, including medically significant cytopaenia (e.g. leukopaenia, pancytopaenia, thrombocytopaenia) have been reported with Cimzia (see section 4.8). All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on Cimzia. Discontinuation of Cimzia therapy should be considered in patients with confirmed significant haematological abnormalities.</p><p>&nbsp;</p><p><u>Neurological events</u></p><p>Use of TNF‑antagonists has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease, including multiple sclerosis. In patients with pre-existing or recent onset of demyelinating disorders, the benefits and risks of TNF‑antagonist treatment should be carefully considered before initiation of Cimzia therapy. Rare cases of neurological disorders, including seizure disorder, neuritis and peripheral neuropathy, have been reported in patients treated with Cimzia.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Severe hypersensitivity reactions have been reported rarely following Cimzia administration. Some of these reactions occurred after the first administration of Cimzia. If severe reactions occur, administration of Cimzia should be discontinued immediately and appropriate therapy instituted.</p><p>&nbsp;</p><p>There are limited data on the use of Cimzia in patients who have experienced a severe hypersensitivity reaction towards another TNF‑antagonist; in these patients caution is needed.</p><p>&nbsp;</p><p><u>Latex-sensitivity </u></p><p>The needle shield inside the removable cap of the CIMZIA pre-filled syringe contains a derivative of natural rubber latex (see section 6.5). Contact with natural rubber latex may cause severe allergic reactions in individuals sensitive to latex. No antigenic latex protein has to date been detected in the removable needle cap of the Cimzia pre-filled syringe. Nevertheless, a potential risk of hypersensitivity reactions cannot be completely excluded in latex-sensitive individuals.</p><p>&nbsp;</p><p><u>Immunosuppression</u></p><p>Since tumour necrosis factor (TNF) mediates inflammation and modulates cellular immune responses, the possibility exists for TNF‑antagonists, including Cimzia, to cause immunosupression, affecting host defences against infections and malignancies.</p><p>&nbsp;</p><p><u>Autoimmunity</u></p><p>Treatment with Cimzia may result in the formation of antinuclear antibodies (ANA) and, uncommonly, in the development of a lupus-like syndrome (see section 4.8). The impact of long-term treatment with Cimzia on the development of autoimmune diseases is unknown. If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with Cimzia, treatment must be discontinued. Cimzia has not been studied specifically in a lupus population (see section 4.8).</p><p>&nbsp;</p><p><u>Vaccinations</u></p><p>Patients treated with Cimzia may receive vaccinations, except for live vaccines. No data are available on the response to live vaccinations or the secondary transmission of infection by live vaccines in patients receiving Cimzia. Live vaccines should not be administered concurrently with Cimzia.</p><p>&nbsp;</p><p>In a placebo-controlled clinical trial in patients with rheumatoid arthritis, similar antibody response between Cimzia and&nbsp; placebo treatment were observed when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with Cimzia. Patients receiving Cimzia and concomitant methotrexate had a lower humoral response compared with patients receiving Cimzia alone. The clinical significance of this is unknown.</p><p>&nbsp;</p><p><u>Concomitant use with other biologics</u></p><p>Severe infections and neutropaenia were reported in clinical trials with concurrent use of anakinra (an interleukin-1 antagonist) or abatacept (a CD28 modulator) and another TNF‑antagonist, etanercept, with no added benefit compared to TNF‑antagonist therapy alone. Because of the nature of the adverse events seen with the combination of another TNF‑antagonist with either abatacept or anakinra therapy, similar toxicities may also result from the combination of anakinra or abatacept and other TNF‑antagonists. Therefore the use of certolizumab pegol in combination with anakinra or abatacept is not recommended (see section 4.5).</p><p><u>&nbsp;</u></p><p><u>Surgery</u></p><p>There is limited safety experience with surgical procedures in patients treated with Cimzia. The 14‑day half-life of certolizumab pegol should be taken into consideration if a surgical procedure is planned. A patient who requires surgery while on Cimzia should be closely monitored for infections, and appropriate actions should be taken.</p><p>&nbsp;</p><p><u>Activated partial thromboplastin time (aPTT) assay</u></p><p>Interference with certain coagulation assays has been detected in patients treated with Cimzia. Cimzia may cause erroneously elevated aPTT assay results in patients without coagulation abnormalities. This effect has been observed with the PTT-Lupus Anticoagulant (LA) test and Standard Target Activated Partial Thromboplastin time (STA-PTT) Automate tests from Diagnostica Stago, and the HemosIL APTT-SP liquid and HemosIL lyophilised silica tests from Instrumentation Laboratories.&nbsp; Other aPTT assays may be affected as well. There is no evidence that Cimzia therapy has an effect on coagulation <em>in vivo</em>. After patients receive Cimzia, careful attention should be given to interpretation of abnormal coagulation results. Interference with thrombin time (TT) and prothrombin time (PT) assays have not been observed.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>In the clinical trials, there was an apparently higher incidence of infections among subjects &ge;&nbsp;65&nbsp;years of age, compared to younger subjects, although experience is limited. Caution should be exercised when treating the elderly patients, and particular attention paid with respect to occurrence of infections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant treatment with methotrexate, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics showed no effect on the pharmacokinetics of certolizumab pegol based on a population pharmacokinetics analysis.</p><p>&nbsp;</p><p>The combination of certolizumab pegol and anakinra or abatacept is not recommended (see section 4.4).</p><p>&nbsp;</p><p>Co-administration of Cimzia with methotrexate had no significant effect on the pharmacokinetics of methotrexate. In study-to-study comparison, the pharmacokinetics of certolizumab pegol appeared similar to those observed previously in healthy subjects.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential </u></p><p>The use of adequate contraception should be considered for women of childbearing potential. For women planning pregnancy, continued contraception may be considered for 5 months after the last Cimzia dose due to its elimination rate (see section 5.2), but the need for treatment of the woman should also be taken into account (see below).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Data from more than &nbsp;1300 prospectively collected pregnancies exposed to Cimzia with known pregnancy outcomes, including more than &nbsp;1000 pregnancies exposed during the first trimester, does not indicate a malformative effect of Cimzia. Further data are being collected as the available clinical experience is&nbsp; still limited toconclude that there is no increased risk associated with Cimzia administration during pregnancy.</p><p>&nbsp;</p><p>Animal studies using a rodent anti-rat TNF&alpha; did not reveal evidence of impaired fertility or harm to the foetus. However, these are insufficient with respect to human reproductive toxicity (see section 5.3). Due to its inhibition of TNF&alpha;, Cimzia administered during pregnancy could affect normal immune response in the newborn.</p><p>&nbsp;</p><p>Cimzia should only be used during pregnancy if clinically needed.</p><p>&nbsp;</p><p>Non-clinical studies suggest low or negligible level of placental transfer of a homologue Fab-fragment of certolizumab pegol (no Fc region) (see section 5.3).</p><p>&nbsp;</p><p>In a clinical study 16 women were treated with certolizumab pegol (200 mg every 2 weeks or 400 mg every 4 weeks) during pregnancy. Certolizumab pegol plasma concentrations measured in 14 infants at birth were Below the Limit of Quantification (BLQ) in 13 samples; one was 0.042 &micro;g/ml with an infant/mother plasma ratio at birth of 0.09%. At Week 4 and Week 8, all infant concentrations were BLQ. The clinical significance of low levels certolizumab pegol for infants is unknown. It is recommended to wait a minimum of 5 months following the mother&rsquo;s last Cimzia administration during pregnancy before administration of live or live-attenuated vaccines (e.g. BCG vaccine), unless the benefit of the vaccination clearly outweighs the theoretical risk of administration of live or live-attenuated vaccines to the infants.</p><p><u>&nbsp;</u></p><p><u>Breastfeeding</u></p><p>In a clinical study in 17 lactating women treated with Cimzia, minimal transfer of certolizumab pegol from plasma to breast milk was observed. The percentage of the maternal certolizumab pegol dose reaching an infant during a 24 hour period was estimated to 0.04% to 0.30 %. In addition, since certolizumab pegol is a protein that is degraded in the gastrointestinal tract after oral administration, the absolute bioavailability is expected to be very low in a breastfed infant.</p><p>&nbsp;</p><p>Consequently, Cimzia can be used during breastfeeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Effects on sperm motility measures and a trend of reduced sperm count in male rodents have been observed with no apparent effect on fertility (see section 5.3).</p><p>&nbsp;</p><p>In a clinical trial to assess the effect of certolizumab pegol on semen quality parameters, 20&nbsp;healthy male subjects were randomized to receive a single subcutaneous dose of 400&nbsp;mg of certolizumab pegol or placebo. During the 14-week follow-up, no treatment effects of certolizumab pegol were seen on semen quality parameters compared to placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cimzia may have a minor influence on the ability to drive and use machines. Dizziness (including vertigo, vision disorder and fatigue) may occur following administration of Cimzia (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p><em><u>Rheumatoid arthritis</u></em></p><p>Cimzia was studied in 4,049&nbsp;patients with rheumatoid arthritis in controlled and open label trials for up to 92&nbsp;months.</p><p>&nbsp;</p><p>In the placebo-controlled studies, patients receiving Cimzia had an approximately 4 times greater duration of exposure compared with the placebo group. This difference in exposure is primarily due to patients on placebo being more likely to withdraw early. In addition, Studies RA‑I and RA‑II had a mandatory withdrawal for non-responders at Week&nbsp;16, the majority of whom were on placebo.</p><p>&nbsp;</p><p>The proportion of patients who discontinued treatment due to adverse events during the controlled trials was 4.4% for patients treated with Cimzia and 2.7% for patients treated with placebo.</p><p>&nbsp;</p><p>The most common adverse reactions belonged to the system organ classes Infections and infestations, reported in 14.4% of patients on Cimzia and 8.0% of patients on placebo, General disorders and administration site conditions, reported in 8.8% of patients on Cimzia and 7.4% of patients on placebo, and Skin and subcutaneous tissue disorders, reported in 7.0% of patients on Cimzia and 2.4% of patients on placebo.</p><p>&nbsp;</p><p><em><u>Axial spondyloarthritis</u></em></p><p>Cimzia was studied in 325&nbsp;patients with active axial spondyloarthritis (including ankylosing spondylitis and non-radiopraphic axial spondyloarthritis) in the AS001 clinical study for up to 4 years, which includes a 24-week placebo-controlled phase followed by a 24-week dose-blind period and a 156-week open-label treatment period. Cimzia was also studied in 317 patients with non-radiographic axial spondyloarthritis in a placebo-controlled study for 52 weeks (AS0006). Cimzia was also studied in a 96-week open-label study in 89 axSpA patients with a history of documented anterior uveitis flares. In all 3 studies, the safety profile for these patients was consistent with the safety profile in rheumatoid arthritis and previous experience with Cimzia.</p><p>&nbsp;</p><p><em><u>Psoriatic arthritis </u></em></p><p>Cimzia was studied in 409&nbsp;patients with psoriatic arthritis in the PsA001 clinical study for up to 4 years which includes a 24-week placebo-controlled phase followed by a 24-week dose-blind period and a 168-week open-label treatment period. The safety profile for psoriatic arthritis patients treated with Cimzia was consistent with the safety profile in rheumatoid arthritis and previous experience with Cimzia.</p><p><u>&nbsp;</u></p><p><em><u>Plaque psoriasis</u></em></p><p>Cimzia was studied in 1112 patients with psoriasis in controlled and open-label studies for up to 3 years. In the Phase III program, the initial and maintenance periods were followed by a 96-week open-label treatment period (see section 5.1). The long-term safety profile of Cimzia 400 mg every 2 weeks and Cimzia 200 mg every 2 weeks was generally similar and consistent with previous experience with Cimzia.</p><p>&nbsp;</p><p>During controlled clinical trials through Week 16, the proportion of patients with serious adverse events was 3.5% for Cimzia and 3.7% for placebo.</p><p>The proportion of patients who discontinued treatment due to adverse events in the controlled clinical studies was 1.5% for patients treated with Cimzia and 1.4% for patients treated with placebo.</p><p>&nbsp;</p><p>The most common adverse reactions reported through Week 16 belonged to the system organ classes Infections and infestations, reported in 6.1% of patients on Cimzia and 7% of patients on placebo, General disorders and administration site conditions, reported in 4.1% of patients on Cimzia and 2.3% of patients on placebo, and Skin and subcutaneous tissue disorders, reported in 3.5% of patients on Cimzia and 2.8% of patients on placebo.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>Adverse reactions based primarily on experience from the placebo-controlled clinical trials and postmarketing cases at least possibly related to Cimzia are listed in Table 1 below, according to frequency and system organ class. Frequency categories are defined as follows: Very common (&ge;&nbsp;1/10); Common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); Uncommon (&ge;&nbsp;1/1000 to &lt;&nbsp;1/100); Rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1000); Very rare (&lt;&nbsp;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Ref216237613'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref216237613'><b style='mso-bidi-font-weight:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'> SEQ Table \* ARABIC \s 1 <span
style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>1</strong><!--[if supportFields]><span
style='mso-bookmark:_Ref216237613'></span><span style='mso-element:field-end'></span><![endif]--><strong> Adverse reactions in clinical trials and postmarketing</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions </strong></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>bacterial infections (including abscess), viral infections (including herpes zoster, papillomavirus, influenza)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>sepsis (including multi-organ failure, septic shock), tuberculosis (including miliary, disseminated and extrapulmonary disease), fungal infections (includes opportunistic)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood and lymphatic system malignancies (including lymphoma and leukaemia), solid organ tumours, non-melanoma skin cancers, pre-cancerous lesions (including oral leukoplakia, melanocytic nevus), benign tumours and cysts (including skin papilloma)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>gastrointestinal tumours, melanoma</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Merkel cell carcinoma*, Kaposi&rsquo;s sarcoma</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Blood and the lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>eosinophilic disorders, leukopaenia (including neutropaenia, lymphopaenia)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>anaemia, lymphadenopathy, thrombocytopaenia, thrombocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>pancytopaenia, splenomegaly, erythrocytosis, white blood cell morphology abnormal</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>vasculitides, lupus erythematosus, drug hypersensitivity (including anaphylactic shock), allergic disorders, auto‑antibody positive</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>angioneurotic oedema, sarcoidosis, serum sickness, panniculitis (including erythema nodosum), worsening of symptoms of dermatomyositis**</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>thyroid disorders</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>electrolyte imbalance, dyslipidaemia, appetite disorders, weight change</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>haemosiderosis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>anxiety and mood disorders (including associated symptoms)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>suicide attempt, delirium, mental impairment</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>headaches (including migraine), sensory abnormalities</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>peripheral neuropathies, dizziness, tremor</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>seizure, cranial nerve inflammation, impaired coordination or balance</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>multiple sclerosis*, Guillain‑Barr&eacute; syndrome*</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>visual disorder (including decreased vision),&nbsp; eye and eyelid inflammation, lacrimation disorder</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>tinnitus, vertigo</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>cardiomyopathies (including heart failure), ischaemic coronary artery disorders , arrhythmias (including atrial fibrillation), palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>pericarditis, atrioventricular block</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>haemorrhage or bleeding (any site), hypercoagulation (including thrombophlebitis, pulmonary embolism), syncope, oedema (including peripheral, facial), ecchymoses (including haematoma, petechiae)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>cerebrovascular accident, arteriosclerosis, Raynaud&rsquo;s phenomenon, livedo reticularis, telangiectasia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>asthma and related symptoms, pleural effusion and symptoms, respiratory tract congestion and inflammation, cough</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>interstitial lung disease, pneumonitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>nausea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>ascites, gastrointestinal ulceration and perforation, gastrointestinal tract inflammation (any site), stomatitis, dyspepsia, abdominal distension, oropharyngeal dryness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>odynophagia, hypermotility</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hepatitis (including hepatic enzyme increased)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hepatopathy (including cirrhosis), cholestasis, blood bilirubin increased</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>cholelithiasis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>rash</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>alopecia, new onset or worsening of psoriasis (including palmoplantar pustular psoriasis) and related conditions, dermatitis and eczema, sweat gland disorder, skin ulcer, photosensitivity, acne, skin discolouration, dry skin, nail and nail bed disorders</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>skin exfoliation and desquamation, bullous conditions, hair texture disorder, Stevens-Johnson syndrome**, erythema multiforme**, lichenoid reactions</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, connective tissue and bone disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>muscle disorders, blood creatine phosphokinase increased</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>renal impairment, blood in urine, bladder and urethral symptoms</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>nephropathy (including nephritis)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>menstrual cycle and uterine bleeding disorders (including amenorrhea), breast disorders</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>sexual dysfunction</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>pyrexia, pain (any site), asthaenia, pruritus (any site), injection site reactions</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>chills, influenza-like illness, altered temperature perception, night sweats, flushing</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>fistula (any site)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood alkaline phosphatase increased, coagulation time prolonged</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>blood uric acid increased</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>skin injuries, impaired healing</p></td></tr></tbody></table><p>*These events have been related to the class of TNF‑antagonists, but incidence with certolizumab pegol is not known.</p><p>**These events have been related to the class of TNF‑antagonists.</p><p>&nbsp;</p><p>The additional following adverse reactions have been observed uncommonly with Cimzia in other indications: gastrointestinal stenosis and obstructions, general physical health deterioration, abortion spontaneous and azoospermia.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em><u>Infections</u></em></p><p>The incidence rate of new cases of infections in placebo-controlled clinical trials in rheumatoid arthritis was 1.03 per patient-year for all Cimzia-treated patients and 0.92 per patient-year for placebo-treated patients. The infections consisted primarily of upper respiratory tract infections, urinary tract infections, and lower respiratory tract infections and herpes viral infections (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>In the placebo-controlled clinical trials in rheumatoid arthritis, there were more new cases of serious infection in the Cimzia treatment groups (0.07 per patient-year; all doses), compared with placebo (0.02 per patient-year). The most frequent serious infections included pneumonia, tuberculosis infections. Serious infections also included invasive opportunistic infections (e.g. pneumocystosis, fungal oesophagitis, nocardiosis and herpes zoster disseminated). There is no evidence of an increased risk of infections with continued exposure over time (see section 4.4).</p><p>&nbsp;</p><p>The incidence rate of new cases of infections in placebo-controlled clinical trials in psoriasis was 1.37 per patient-year for all Cimzia-treated patients and 1.59 per patient-year for placebo-treated patients. The infections consisted primarily of upper respiratory tract infections and viral infections (including herpes infections). The incidence of serious infections was 0.02 per patient-year in Cimzia treated patients.&nbsp; No serious infections were reported in the placebo-treated patients. There is no evidence of an increased risk of infections with continued exposure over time.</p><p>&nbsp;</p><p><em><u>Malignancies and lymphoproliferative disorders</u></em></p><p>Excluding non-melanoma of the skin, 121 malignancies including 5 cases of lymphoma were observed in the Cimzia RA clinical trials in which a total of 4,049 patients were treated, representing 9,277 patient-years. Cases of lymphoma occurred at an incidence rate of 0.05 per 100 patient-years and melanoma at an incidence rate of 0.08 per 100 patient-years with Cimzia in rheumatoid arthritis clinical trials (see section 4.4). One case of lymphoma was also observed in the Phase III psoriatic arthritis clinical trial.</p><p>&nbsp;</p><p>Excluding non-melanoma skin cancer, 11 malignancies including 1 case of lymphoma were observed in the Cimzia psoriasis clinical trials in which a total of 1112 patients were treated, representing 2300 patient-years.</p><p>&nbsp;</p><p><em><u>Autoimmunity</u></em></p><p>In the rheumatoid arthritis pivotal studies, for subjects who were ANA negative at baseline, 16.7% of those treated with Cimzia developed positive ANA titers, compared with 12.0% of subjects in the placebo group. For subjects who were anti-dsDNA antibody negative at baseline, 2.2% of those treated with Cimzia developed positive anti-dsDNA antibody titers, compared with 1.0% of subjects in the placebo group. In both placebo-controlled and open-label follow-up clinical trials for rheumatoid arthritis, cases of lupus-like syndrome were reported uncommonly. There have been rare reports of other immune-mediated conditions; the causal relationship to Cimzia is not known. The impact of long-term treatment with Cimzia on the development of autoimmune diseases is unknown.</p><p>&nbsp;</p><p><em><u>Injection site reactions</u></em></p><p>In the placebo-controlled rheumatoid arthritis clinical trials, 5.8% of patients treated with Cimzia developed injection site reactions such as erythema, itching, haematoma, pain, swelling or bruising, compared to 4.8% of patients receiving placebo. Injection site pain was observed in 1.5% of patients treated with Cimzia with no cases leading to withdrawal.</p><p>&nbsp;</p><p><em><u>Creatine phosphokinase elevations</u></em></p><p>The frequency of creatine phosphokinase (CPK) elevations was generally higher in patients with axSpA as compared to the RA population. The frequency was increased both in patients treated with placebo (2.8% vs 0.4% in axSpA and RA populations, respectively) as well as in patients treated with Cimzia (4.7% vs 0.8% in axSpA and RA populations, respectively). The CPK elevations in the axSpA study were mostly mild to moderate, transient in nature and of unknown clinical significance with no cases leading to withdrawal.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No dose-limiting toxicity was observed during clinical trials. Multiple doses of up to 800&nbsp;mg subcutaneously and 20&nbsp;mg/kg intravenously have been administered. In cases of overdose, it is recommended that patients are monitored closely for any adverse reactions or effect, and appropriate symptomatic treatment initiated immediately.</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
 margin-left:14.25pt;margin-top:.05pt;width:300pt;height:71.25pt;z-index:251661312;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA8k/ASWAEAACxGQAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWc1u4zYQvhfoOxA8tYfYsmLnR1hl
6/XGiwJpasRZ9DymKJsoRaok/bfHPknfove+UF+hQ0q25QTrAm7apqhl2CbF0aeZb4YjcvTm7aqQ
ZMGNFVqltNOKKOGK6UyoaUo/Pg7PriixDlQGUiue0jW39O3Nl1+8gWRqoJwJRhBB2QRSOnOuTNpt
y2a8ANvSJVc4lmtTgMOumbYzA0tELmQ7jqKLdgFC0Zsd1HtwQOZGHAElNfuRZwNQC7AIKVnSPFPr
KNlfR4ZELT6YclyOjNec3S9GhogspcicggIpou16oBbDbvvJVdMdwCo3hZfXeU5W6IHound+2aNk
ndLrTi8671VwfOUIw/Hzq06EByXMC0TdK5St7jf7/jACm90exkAlK2Ww0VDQll49tXhucbyx+NFr
906vSLy13UsTt8KTaFPwsS3v0EeWKD2YgZryvjF6OeOQWS9RkYRsVrcJhG3uaD3WZPmdzpBdmDsd
8F6GuK3RkJTGug9cF8Q3Umo4c+FGsLizrtJvI+IZsVqKbCikDB0znQykIQuQKR2GozZpT0wqskS3
9eJeRclnIbyP0cvVXfcgCuG4IVIUKb3aCkHiibxVWQgFB0JWbbROqhB+nkOvqFuNgz+9a7K1PzPB
f+TXaLQZ4wpzATZm2nyiZIkzPKX2pzkYTon8VqGrrjvdLoq50On2LmPsmObIpDkCiiFUSh0lVXPg
sBcF65Xuoy9zUXNb6eE1ktaN3VryYEzQ1gdAAeYO478bX/vwx95D0FcukHE8IVTGFWp+VksEIDUu
mW/Yko2Yq7zTiS531MqGxDueb2SdrWS3HijZbrSfuwNy9ehkPtTKEbcueQ4M43a8LiZaUlKC0hb7
UQ8/nSjG72V0gf+96BJHhWOzIRRC4vTuYO5lMzCWo1311JrMcfaYcDqlv//8ax0itXeDiw2SJXGG
pZSrs/4t5u9PiIW55OiY43mOk6GaBegecEI1LHsUBbfkni/Jgy5ANUyM0ayL6BxN6+I3xlb3kImB
bUg4NMAHIMXEiD3QYQDz4F2ExN8noOd4YstbDcpsA7RvBDRdEUfvUM8uQm0+fw6JUwuJ9oHgbh5n
nNwjK1qBJCP0TwFML8RUoBsYJwMMTMPJV/ejwdcJ8Q8DDCB/vb+aq2wEBh6aTvs43jgNQz3E2hGJ
4rDTXorX/4yzdjwH7qu04rk95ZZTbtnk5Dh6dbllPHzfJzhbZUgj3CSkc43HKY3sPyv/qZx/SiP/
6hKlexEPNpuFvWXx4afdaYlye4abbZkQVbJWZubTb2yeQWuqFy0LL51LjnTSaUniVyOnJclpu/PK
tzs/8InFKsSzrUzYzxy9+zwya5xSuy+7Wqy7QsZbjazePqX1V7tEbBSwfL5vVqH+1joVVgw3NcWS
hUoVliE+Wzt6VoY4vMj63z2/t/Wf337ZK+p4TkORYVdknVs+Lh+wiFZVdKsqLMr54nr7ycuKcGn9
csW/EWn2b/4AAAD//wMAUEsDBBQABgAIAAAAIQCSfYfgHQcAAEkgAAAaAAAAY2xpcGJvYXJkL3Ro
ZW1lL3RoZW1lMS54bWzsWUtvGzcQvhfof1jsvbFkvWIjcmDJctzEL0RKihwpidplzF0uSMqObkVy
6qVAgbTooQF666EoGqABGvTSH2PAQZv+iA65L1Ki4gdcIChsAcbu7DfD4czszOzwzt1nEfWOMReE
xW2/eqviezgesTGJg7b/aLD92W3fExLFY0RZjNv+DAv/7sann9xB6yNKkiFDfDwIcYQ9EBSLddT2
QymT9ZUVMQIyErdYgmN4NmE8QhJuebAy5ugEFojoymql0lyJEIn9DZAolaAehX+xFIoworyvxGAv
RhGsfjCZkBHW2PFRVSHETHQp944Rbfsgc8xOBviZ9D2KhIQHbb+i//yVjTsraD1jonIJr8G3rf8y
voxhfLSq1+TBsFi0Xm/Um5uFfA2gchHXa/WavWYhTwPQaAQ7TXWxZbZWu/UMa4DSS4fsrdZWrWrh
Dfm1BZ03G+pn4TUolV9fwG9vd8GKFl6DUnxjAd/orHW2bPkalOKbC/hWZXOr3rLka1BISXy0gK40
mrVuvtsCMmF0xwlfa9S3W6uZ8BIF0VBEl1piwmK5LNYi9JTxbQAoIEWSxJ6cJXiCRhCTXUTJkBNv
lwQhBF6CYiaAXFmtbFdq8F/96vpKexStY2RwK71AE7FAUvp4YsRJItv+fZDqG5Czt29Pn785ff77
6YsXp89/zdbWoiy+HRQHJt/7n77559WX3t+//fj+5bfp0vN4YeLf/fLVuz/+/JB42HFpirPvXr97
8/rs+6//+vmlQ/omR0MTPiARFt4+PvEesgg26NAfD/nlOAYhIibHZhwIFCO1ikN+T4YWen+GKHLg
Oti242MOqcYFvDd9aincD/lUEofEB2FkAfcYox3GnVZ4oNYyzDyYxoF7cT41cQ8ROnat3UWx5eXe
NIEcS1wiuyG21DykKJYowDGWnnrGjjB27O4JIZZd98iIM8Em0ntCvA4iTpMMyNCKppJph0Tgl5lL
QfC3ZZu9x16HUdeut/CxjYR3A1GH8gNMLTPeQ1OJIpfIAYqoafBdJEOXkv0ZH5m4npDg6QBT5vXG
WAgXzwGH/RpOfwBpxu32PTqLbCSX5MglcxcxZiK32FE3RFHiwvZJHJrYz8URhCjyDpl0wfeY/Yao
e/ADipe6+zHBlrvPzwaPIMOaKpUBop5MucOX9zCz4rc/oxOEXalmk0dWit3kxBkdnWlghfYuxhSd
oDHG3qPPHRp0WGLZvFT6fghZZQe7Aus+smNV3cdYYE83N4t5cpcIK2T7OGBL9NmbzSWeGYojxJdJ
3gevmzbvQamLXAFwQEdHJnCfQL8H8eI0yoEAGUZwL5V6GCKrgKl74Y7XGbf8d5F3DN7Lp5YaF3gv
gQdfmgcSu8nzQdsMELUWKANmgKDLcKVbYLHcX7Ko4qrZpk6+if3Slm6A7shqeiISn9sBzfU+jf+u
94EO4+yHV46X7Xr6HbdgK1ldstNZlkx25vqbZbj5rqbL+Jh8/E3NFprGhxjqyGLGuulpbnoa/3/f
0yx7n286mWX9xk0n40OHcdPJZMOV6+lkyuYF+ho18EgHPXrsEy2d+kwIpX05o3hX6MGPgO+Z8TYQ
FZ+ebuJiCpiEcKnKHCxg4QKONI/HmfyCyLAfogSmQ1VfCQlEJjoQXsIEDI002Slb4ek02mPjdNhZ
rarBZlpZBZIlvdIo6DCokim62SoHeIV4rW2gB625Aor3MkoYi9lK1BxKtHKiMpIe64LRHEronV2L
FmsOLW4r8bmrFrQA1QqvwAe3B5/pbb9RBxZggnkcNOdj5afU1bl3tTOv09PLjGlFADTYeQSUnl5T
ui7dntpdGmoX8LSlhBFuthLaMrrBEyF8BmfRqagXUeOyvl4rXWqpp0yh14PQKtVo3f6QFlf1NfDN
5wYam5mCxt5J22/WGhAyI5S0/QkMjeEySiB2hPrmQjSA45aR5OkLf5XMknAht5AIU4PrpJNmg4hI
zD1Koravtl+4gcY6h2jdqquQED5a5dYgrXxsyoHTbSfjyQSPpOl2g6Isnd5Chk9zhfOpZr86WHGy
Kbi7H45PvCGd8ocIQqzRqioDjomAs4Nqas0xgcOwIpGV8TdXmLK0a55G6RhK6YgmIcoqipnMU7hO
5YU6+q6wgXGX7RkMapgkK4TDQBVY06hWNS2qRqrD0qp7PpOynJE0y5ppZRVVNd1ZzFohLwNztrxa
kTe0yk0MOc2s8Gnqnk+5a3mum+sTiioBBi/s56i6FygIhmrlYpZqSuPFNKxydka1a0e+wXNUu0iR
MLJ+Mxc7Z7eiRjiXA+KVKj/wzUctkCZ5X6kt7TrY3kOJNwyqbR8Ol2E4+Ayu4HjaB9qqoq0qGlzB
mTOUi/SguO1nFzkFnqeUAlPLKbUcU88p9ZzSyCmNnNLMKU3f0yeqcIqvDlN9Lz8whRqWHbBmvYV9
+r/xLwAAAP//AwBQSwMEFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJhd2lu
Z3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHOEj80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/
JFHs2xvoRUHwsjCz7DezTfuyM3liTJN3HGpaAUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201zxVnm
cpTGKSRSKC5xGHMOJ8aSGtHKRH1AVzaDj1bmIqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n
+2GYFJ69elh0+UcEy6UXFqCMBjMHSldnnTUtXYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAh
ALvlSJQFAQAAHgIAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAU
AAYACAAAACEArTA/8cEAAAAyAQAACwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAU
AAYACAAAACEA8k/ASWAEAACxGQAAHwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdz
L2RyYXdpbmcxLnhtbFBLAQItABQABgAIAAAAIQCSfYfgHQcAAEkgAAAaAAAAAAAAAAAAAAAAAL0G
AABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQBAAAq
AAAAAAAAAAAAAAAAABIOAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJl
bHNQSwUGAAAAAAUABQBnAQAAFQ8AAAAA
">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <ul style='margin-top:0in' type=disc>
     <li class=MsoNormal style='color:black;margin-bottom:0in;margin-bottom:
         .0001pt;line-height:normal;mso-list:l0 level1 lfo3;mso-layout-grid-align:
         none;text-autospace:none'><span lang=en-AE style='font-size:11.5pt;
         font-family:"Times New Roman",serif;mso-ansi-language:#4C09'>The
         National Pharmacovigilance Centre (NPC): <o:p></o:p></span></li>
     <li class=MsoNormal style='color:black;margin-bottom:0in;margin-bottom:
         .0001pt;line-height:normal;mso-list:l0 level1 lfo3;mso-layout-grid-align:
         none;text-autospace:none'><span lang=en-AE style='font-size:11.5pt;
         font-family:"Times New Roman",serif;mso-ansi-language:#4C09'>SFDA Call
         Center: 19999 <o:p></o:p></span></li>
     <li class=MsoNormal style='color:#0462C1;margin-bottom:0in;margin-bottom:
         .0001pt;line-height:normal;mso-list:l0 level1 lfo3;mso-layout-grid-align:
         none;text-autospace:none'><span lang=en-AE style='font-size:11.5pt;
         font-family:"Times New Roman",serif;mso-ansi-language:#4C09'>E-mail:
         npc.drug@sfda.gov.sa <o:p></o:p></span></li>
     <li class=MsoNormal style='color:#0462C1;margin-bottom:0in;margin-bottom:
         .0001pt;line-height:normal;mso-list:l0 level1 lfo3;mso-layout-grid-align:
         none;text-autospace:none'><span lang=en-AE style='font-size:11.5pt;
         font-family:"Times New Roman",serif;color:black;mso-ansi-language:
         #4C09'>Website: </span><span lang=en-AE style='font-size:11.5pt;
         font-family:"Times New Roman",serif;mso-ansi-language:#4C09'>https://ade.sfda.gov.sa/
         <o:p></o:p></span></li>
    </ul>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="406" height="101" alt="Text Box: •	The National Pharmacovigilance Centre (NPC): 
•	SFDA Call Center: 19999 
•	E-mail: npc.drug@sfda.gov.sa 
•	Website: https://ade.sfda.gov.sa/ 

" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC states:</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_2"
 o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 margin-left:31.5pt;margin-top:1pt;width:333pt;height:25.5pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
    0in;margin-left:21.0pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:
    13.0pt;mso-line-height-rule:exactly;mso-list:l1 level1 lfo2;tab-stops:28.35pt'><![if !supportLists]><span
    style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><span style='mso-list:Ignore'>-<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='mso-bidi-font-size:
    10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'>Please
    contact the relevant authority<o:p></o:p></span></p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="450" height="40" alt="Text Box: -	Please contact the relevant authority

" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: immunosuppressants, tumour necrosis factor alpha (TNF&alpha;) inhibitors, ATC code: L04AB05</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Cimzia has a high affinity for human TNF&alpha; and binds with a dissociation constant (KD) of 90&nbsp;pM. TNF&alpha; is a key pro-inflammatory cytokine with a central role in inflammatory processes. Cimzia selectively neutralises TNF&alpha; (IC90 of 4&nbsp;ng/ml for inhibition of human TNF&alpha; in the <em>in vitro</em> L929 murine fibrosarcoma cytotoxicity assay) but does not neutralise lymphotoxin &alpha; (TNF&beta;).</p><p>&nbsp;</p><p>Cimzia was shown to neutralise membrane associated and soluble human TNF&alpha; in a dose-dependent manner. Incubation of monocytes with Cimzia resulted in a dose-dependent inhibition of lipopolysaccharide (LPS)-induced TNF&alpha; and IL1&beta; production in human monocytes.</p><p>&nbsp;</p><p>Cimzia does not contain a fragment crystallisable (Fc) region, which is normally present in a complete antibody, and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity <em>in vitro</em>. It does not induce apoptosis <em>in vitro</em> in human peripheral blood-derived monocytes or lymphocytes, or neutrophil degranulation.</p><p><u>&nbsp;</u></p><p><u>Clinical efficac</u></p><p><em><u>&nbsp;</u></em></p><p><em><u>Rheumatoid arthritis</u></em></p><p>The efficacy and safety of Cimzia have been assessed in 2 randomised, placebo-controlled, double-blind clinical trials in patients &ge;&nbsp;18&nbsp;years of age with active rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria, RA‑I (RAPID 1) and RA‑II (RAPID 2). Patients had &ge;&nbsp;9 swollen and tender joints each and had active RA for at least 6 months prior to baseline. Cimzia was administered subcutaneously in combination with oral MTX for a minimum of 6&nbsp;months with stable doses of at least 10&nbsp;mg weekly for 2 months in both trials. There is no experience with Cimzia in combination with DMARDs other than MTX.</p><p>&nbsp;</p><p>The efficacy and safety of Cimzia was assessed in DMARD-na&iuml;ve adult patients with active RA in a randomized, placebo-controlled, double-blind clinical trial (C‑EARLY). In the C‑EARLY trial patients were &ge;&nbsp;18&nbsp;years of age and had &ge; 4 swollen and tender joints each and must have been diagnosed with moderate to severe active and progressive RA within 1&nbsp;year (as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria). Patients had a mean time since diagnosis at baseline of 2.9&nbsp;months and were DMARD na&iuml;ve (including MTX). For both the Cimzia and placebo arms, MTX was initiated as of Week 0 (10 mg/week), titrated up to maximum tolerated dose by Week&nbsp; 8 (min 15&nbsp;mg/week, max 25&nbsp;mg/week allowed), and maintained throughout the study (average dose of MTX after Week&nbsp;8 for placebo and Cimzia was 22.3&nbsp;mg/week and 21.1&nbsp;mg/week respectively).</p><p>&nbsp;</p><p><strong>Table&nbsp;2 Clinical trial description</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Study number</strong></p></td><td style="vertical-align:top"><p><strong>Patient numbers</strong></p></td><td style="vertical-align:top"><p><strong>Active dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Study objectives</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>RA-I<br />(52 weeks)</p></td><td style="vertical-align:top"><p>982</p></td><td style="vertical-align:top"><p>400&nbsp;mg (0,2,4 weeks) with MTX</p><p>200&nbsp;mg or 400&nbsp;mg every 2 weeks<sup> </sup>with MTX</p></td><td style="vertical-align:top"><p>Evaluation for treatment of signs and symptoms and inhibition of structural damage.</p><p>Co-primary endpoints: ACR&nbsp;20 at Week&nbsp;24 and change from baseline in mTSS at Week&nbsp;52</p></td></tr><tr><td style="vertical-align:top"><p>RA-II</p><p>(24 weeks)</p></td><td style="vertical-align:top"><p>619</p></td><td style="vertical-align:top"><p>400&nbsp;mg (0,2,4 weeks) with MTX</p><p>200&nbsp;mg or 400&nbsp;mg every 2&nbsp;weeks with MTX</p></td><td style="vertical-align:top"><p>Evaluation for treatment of signs and symptoms and inhibition of structural damage.</p><p>Primary endpoint: ACR&nbsp;20 at Week&nbsp;24.</p></td></tr><tr><td style="vertical-align:top"><p>C-EARLY</p><p>(to 52&nbsp;weeks)</p></td><td style="vertical-align:top"><p>879</p></td><td style="vertical-align:top"><p>400&nbsp;mg (0,2,4 weeks) with MTX</p><p>200&nbsp;mg every 2 weeks with MTX</p></td><td style="vertical-align:top"><p>Evaluation for treatment of signs and symptoms and inhibition of structural damage&nbsp; in DMARD na&iuml;ve patients.</p><p>Primary endpoint: proportion of subjects in sustained remission* at Week&nbsp;52</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>mTSS: modified Total Sharp Score</p><p>*Sustained remission at Week 52 is defined as DAS28[ESR] &lt;2.6 at both Week 40 and Week 52.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Signs and symptoms</em></p><p>The results of clinical trials RA-I and RA-II are shown in Table 3. Statistically significantly greater ACR&nbsp;20 and ACR&nbsp;50 responses were achieved from Week&nbsp;1 and Week&nbsp;2, respectively, in both clinical trials compared to placebo. Responses were maintained through Weeks&nbsp;52 (RA‑I) and 24 (RA-II). Of the 783 patients initially randomised to active treatment in RA‑I, 508 completed 52&nbsp;weeks of placebo-controlled treatment and entered the open-label extension study. Of these, 427 completed 2&nbsp;years of open-label follow-up and thus had a total exposure to Cimzia of 148 weeks overall. The observed ACR&nbsp;20 response rate at this timepoint was 91%.The reduction (RA‑I) from Baseline in DAS28 (ESR) also was significantly greater (p&lt;0.001) at Week&nbsp;52 (RA‑I) and Week&nbsp;24 (RA‑II) compared to placebo and maintained through 2&nbsp;years in the open-label extension trial to RA‑I.</p><p>&nbsp;</p><p><strong>Table&nbsp;3 ACR response in clinical trials RA-I and RA-II</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study RA-I</strong></p><p><strong>Methotrexate combination</strong></p><p><strong>(24 and 52 weeks)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study RA-II</strong></p><p><strong>Methotrexate combination</strong></p><p><strong>(24 weeks)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Response</p></td><td style="vertical-align:top"><p>Placebo + MTX</p><p>&nbsp;</p><p>N=199</p></td><td style="vertical-align:top"><p>Cimzia<br />200&nbsp;mg + MTX every 2 weeks</p><p>&nbsp;</p><p>N=393</p></td><td style="vertical-align:top"><p>Placebo + MTX</p><p>&nbsp;</p><p>N=127</p></td><td style="vertical-align:top"><p>Cimzia<br />200&nbsp;mg + MTX every 2 weeks</p><p>&nbsp;</p><p>N=246</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR 20</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>59%**</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>57%**</p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>53%**</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR 50</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>37%**</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>33%**</p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>38%**</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR 70</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>21%**</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>16%*</p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>21%**</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p>Major Clinical Response<sup>a.</sup></p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>13%**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Cimzia vs. placebo: *p&le;0.01, ** p&lt;0.001</p><p><sup>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Major clinical response is defined as achieving ACR&nbsp;70 response at every assessment over a continuous 6‑month period</p><p>Wald p-values are quoted for the comparison of treatments using logistic regression with factors for treatment and region.</p><p>Percentage response based upon number of subjects contributing data (n) to that endpoint and time point which may differ from N</p></td></tr></tbody></table><p>&nbsp;</p><p>The C-EARLY trial met its primary and key secondary endpoints. The key results from the study are presented in table 4.</p><p>&nbsp;</p><p><strong>Table 4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; C-EARLY trial: percent of patients in sustained remission and sustained low disease activity at Week 52</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Response</p></td><td style="vertical-align:top"><p>Placebo+MTX</p><p>N= 213</p></td><td style="vertical-align:top"><p>Cimzia 200&nbsp;mg + MTX</p><p>N= 655</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sustained remission*</strong></p><p>(DAS28(ESR) &lt;2.6 at both Week 40 and Week 52)</p></td><td style="vertical-align:top"><p>15.0 %</p></td><td style="vertical-align:top"><p>28.9%**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sustained low disease activity</strong></p><p>(DAS28(ESR) &le;3.2 at both Week 40 and Week 52)</p></td><td style="vertical-align:top"><p>28.6 %</p></td><td style="vertical-align:top"><p>43.8%**</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Primary endpoint of C-EARLY trial (to Week&nbsp;52)</p><p>Full analysis set, non-responder imputation for missing values.</p><p>**Cimzia+MTX vs placebo+MTX: p&lt;0.001</p><p>p value was estimated from a logistic regression model with factors for treatment, region, and time since RA diagnosis at Baseline (&le;4 months vs &gt;4 months)</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>Patients in the Cimzia+MTX group had a greater reduction from baseline in DAS 28 (ESR) compared with the placebo+MTX group observed as early as Week 2 and continued through Week 52 (p&lt;0.001 at each visit). Assessments on remission (DAS28(ESR) &lt;2.6), Low Disease Activity (DAS28(ESR) &le;3.2) status, ACR50 and ACR 70 by visit demonstrated that Cimzia+MTX treatment led to faster and greater responses than PBO+MTX treatment. These results were maintained over 52 weeks of treatment in DMARD-na&iuml;ve subjects.</p><p><em>&nbsp;</em></p><p><em>Radiographic response</em></p><p>In RA‑I, structural joint damage was assessed radiographically and expressed as change in mTSS and its components, the erosion score and joint space narrowing (JSN) score, at Week&nbsp;52, compared to baseline. Cimzia patients demonstrated significantly less radiographic progression than patients receiving placebo at Week&nbsp;24 and Week&nbsp;52 (see Table 5). In the placebo group, 52% of patients experienced no radiographic progression (mTSS &le;&nbsp;0.0) at Week 52 compared to 69% in the Cimzia 200&nbsp;mg treatment group.</p><p>&nbsp;</p><p><strong>Table&nbsp;5 Changes over 12 months in RA-I</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo + MTX</strong></p><p><strong>N=199</strong></p><p><strong>Mean (SD)</strong></p></td><td style="vertical-align:top"><p><strong>Cimzia 200&nbsp;mg + MTX</strong></p><p><strong>N=393</strong></p><p><strong>Mean (SD)</strong></p></td><td style="vertical-align:top"><p><strong>Cimzia 200&nbsp;mg + MTX &ndash;</strong></p><p><strong>Placebo + MTX</strong></p><p><strong>Mean Difference</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>mTSS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>2.8 (7.8)</p></td><td style="vertical-align:top"><p>0.4 (5.7)</p></td><td style="vertical-align:top"><p>-2.4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Erosion Score</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>1.5 (4.3)</p></td><td style="vertical-align:top"><p>0.1 (2.5)</p></td><td style="vertical-align:top"><p>-1.4</p></td></tr><tr><td style="vertical-align:top"><p><strong>JSN Score</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>1.4 (5.0)</p></td><td style="vertical-align:top"><p>0.4 (4.2)</p></td><td style="vertical-align:top"><p>-1.0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>p-values were &lt;&nbsp;0.001 for both mTSS and erosion score and &le;&nbsp;0.01 for JSN score. An ANCOVA was fitted to the ranked change from baseline for each measure with region and treatment as factors and rank baseline as a covariate.</p></td></tr></tbody></table><p>&nbsp;</p><p>Of the 783 patients initially randomised to active treatment in RA‑I, 508 completed 52&nbsp;weeks of placebo-controlled treatment and entered the open-label extension study. Sustained inhibition of progression of structural damage was demonstrated in a subset of 449 of these patients who completed at least 2&nbsp;years of treatment with Cimzia (RA‑I and open‑label extension study) and had evaluable data at the 2‑year timepoint.</p><p>&nbsp;</p><p>In C-EARLY, Cimzia+ MTX inhibited the radiographic progression compared to placebo+MTX at Week 52 (see Table 6). In the placebo+MTX group, 49.7% of patients experienced no radiographic progression (change in mTSS &le;0.5) at Week 52 compared to 70.3% in the Cimzia+MTX group (p&lt;0.001).</p><p>&nbsp;</p><p><strong>Table 6 Radiographic change at Week 52 in trial C-EARLY</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo +MTX</strong></p><p>N= 163</p><p>Mean (SD)</p></td><td style="vertical-align:top"><p><strong>Cimzia 200&nbsp;mg + MTX</strong></p><p>N = 528</p><p>Mean (SD)</p></td><td style="vertical-align:top"><p><strong>Cimzia 200&nbsp;mg + MTX &ndash;</strong></p><p><strong>Placebo +MTX</strong></p><p>Difference*</p></td></tr><tr><td style="vertical-align:top"><p><strong>mTSS</strong></p><p>Week 52</p></td><td style="vertical-align:top"><p>1.8 (4.3)</p></td><td style="vertical-align:top"><p>0.2 (3.2)**</p></td><td style="vertical-align:top"><p>-0.978 (-1.005, -0.500)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Erosion score</strong></p><p>Week 52</p></td><td style="vertical-align:top"><p>1.1 (3.0)</p></td><td style="vertical-align:top"><p>0.1 (2.1)**</p></td><td style="vertical-align:top"><p>-0.500 (-0.508, -0.366)</p></td></tr><tr><td style="vertical-align:top"><p><strong>JSN score</strong></p><p>Week 52</p></td><td style="vertical-align:top"><p>0.7 (2.3)</p></td><td style="vertical-align:top"><p>0.1 (1.7)**</p></td><td style="vertical-align:top"><p>0.000 (0.000, 0.000)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Radiographic set with linear extrapolation.</p><p>* Hodges-Lehmann point estimate of shift and 95% asymptotic (Moses) confidence interval.</p><p>**Cimzia+MTX vs placebo+MTX p&lt;0.001. p value was estimated from an ANCOVA model on the ranks with treatment, region, time since RA diagnosis at Baseline (&le;4 months vs &gt;4 months) as factors and Baseline rank as a covariate.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Physical function response and health-related outcomes</em></p><p>In RA‑I and RA‑II, Cimzia‑treated patients reported significant improvements in physical function as assessed by the Health Assessment Questionnaire &ndash; Disability Index (HAQ‑DI) and in tiredness (fatigue) as reported by the Fatigue Assessment Scale (FAS) from Week 1 through to the end of the studies compared to placebo. In both clinical trials, Cimzia‑treated patients reported significantly greater improvements in the SF‑36 Physical and Mental Component Summaries and all domain scores. Improvements in physical function and HRQoL were maintained through 2 years in the open-label extension to RA‑I. Cimzia-treated patients reported statistically significant improvements in the Work Productivity Survey compared to placebo.</p><p>&nbsp;</p><p>In C-EARLY, Cimzia+MTX-treated patients reported significant improvements at Week&nbsp;52 compared to placebo+MTX in pain as assessed by the Patient Assessment of Arthritis Pain (PAAP) &ndash;&nbsp;48,5 vs -&nbsp;44,0 (least square mean) (p&lt;0.05).</p><p>&nbsp;</p><p><em>DoseFlex clinical trial</em></p><p>The efficacy and safety of 2&nbsp;dose regimens (200&nbsp;mg every 2&nbsp;weeks and 400&nbsp;mg every 4&nbsp;weeks) of Cimzia versus placebo were assessed in an 18-week, open-label, run-in, and 16‑week randomised, double-blind, placebo‑controlled clinical trial in adult patients with active rheumatoid arthritis diagnosed according to the ACR criteria who had inadequate response to MTX.</p><p>&nbsp;</p><p>Patients received loading doses of Cimzia 400&nbsp;mg at weeks&nbsp;0, 2, and 4 followed by Cimzia 200&nbsp;mg every 2&nbsp;weeks during the initial open label period. Responders (achieved ACR&nbsp;20) at week 16 were randomised at week&nbsp;18 to Cimzia 200&nbsp;mg every 2&nbsp;weeks, Cimzia 400&nbsp;mg every 4&nbsp;weeks, or placebo in combination with MTX for an additional 16&nbsp;weeks (total trial length: 34&nbsp;weeks). These 3 groups were well balanced with regards to clinical response following the active run-in period (ACR&nbsp;20: 83‑84% at week&nbsp;18).</p><p>&nbsp;</p><p>The primary endpoint of the study was the ACR&nbsp;20 responder rate at week&nbsp;34. The results at week&nbsp;34 are shown in Table&nbsp;7. Both Cimzia regimens showed sustained clinical response and were statistically significant compared to placebo at week&nbsp;34. The ACR&nbsp;20 endpoint was achieved for both Cimzia 200&nbsp;mg every 2&nbsp;weeks and 400&nbsp;mg every 4&nbsp;weeks.</p><p>&nbsp;</p><p><strong>Table&nbsp;7 ACR response in DoseFlex clinical trial at week&nbsp;34</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment regimen week 0 to 16</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Cimzia 400&nbsp;mg + MTX at week 0, 2 and 4, followed by Cimzia 200&nbsp;mg </strong><strong>+ MTX</strong><strong> every 2&nbsp;weeks </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Randomised, double-blind treatment regimen week 18 to 34</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo + MTX</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=69</strong></p></td><td style="vertical-align:top"><p><strong>Cimzia<br />200&nbsp;mg + MTX every 2&nbsp;weeks</strong></p><p><strong>N=70</strong></p></td><td style="vertical-align:top"><p><strong>Cimzia<br />400&nbsp;mg + MTX every 4&nbsp;weeks</strong></p><p><strong>N=69</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR&nbsp;20</strong></p><p>p-value*</p></td><td style="vertical-align:top"><p>45%</p><p>N/A</p></td><td style="vertical-align:top"><p>67%</p><p>0.009</p></td><td style="vertical-align:top"><p>65%</p><p>0.017</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR&nbsp;50</strong></p><p>p-value*</p></td><td style="vertical-align:top"><p>30%</p><p>N/A</p></td><td style="vertical-align:top"><p>50%</p><p>0.020</p></td><td style="vertical-align:top"><p>52%</p><p>0.010</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR&nbsp;70</strong></p><p>p-value*</p></td><td style="vertical-align:top"><p>16%</p><p>N/A</p></td><td style="vertical-align:top"><p>30%</p><p>0.052</p></td><td style="vertical-align:top"><p>38%</p><p>0.005</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>N/A: Not Applicable</p><p>*Wald p-values for Cimzia 200&nbsp;mg vs. placebo and Cimzia 400&nbsp;mg vs. placebo comparisons are estimated from a logistic regression model with factors for treatment</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Axial spondyloarthritis </u></em><u>&nbsp;<em>(non-radiographic axial spondyloarthritis and ankylosing spondylitis subpopulations)</em></u></p><p>The efficacy and safety of Cimzia were assessed in one multicenter, randomized, double-blind, placebo‑controlled trial (AS001) in 325&nbsp;patients &ge;18&nbsp;years of age with adult-onset active axial spondyloarthritis for at least 3 months as defined by the Assessment of Spondyloarthritis International Society (ASAS) Classification Criteria for axial spondyloarthritis. The axial spondyloarthritis overall population included subpopulations with and without (non-radiographic axial spondyloarthritis [nr-axSpA]) radiographic evidence for ankylosing spondylitis (AS) (also known as radiographic axial spondyloarthritis).&nbsp; Patients had active disease as defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) &ge;&nbsp;4, spinal pain &ge;&nbsp;4 on a 0 to 10 Numerical Rating Scale (NRS) and increased CRP or current evidence of sacroiliitis on Magnetic Resonance Imaging (MRI). Patients must have been intolerant to or had an inadequate response to at least one NSAID. Overall, 16% of patients had prior TNF‑antagonist exposure. Patients were treated with a loading dose of Cimzia 400&nbsp;mg at Weeks&nbsp;0, 2 and 4 (for both treatment arms) or placebo followed by either 200&nbsp;mg of Cimzia every 2&nbsp;weeks or 400&nbsp;mg of Cimzia every 4&nbsp; weeks or placebo. 87.7% of patients received concomitant NSAIDs. The primary efficacy endpoint was the ASAS20 response rate at Week&nbsp;12. The 24-week double-blind, placebo-controlled treatment period of the study was followed by a 24-week dose-blind treatment period, and a 156-week open-label treatment period . The maximum duration of the study was 204 weeks. All patients received Cimzia in both the dose-blind and open-label follow-up periods. A total of 199 subjects (61.2% of randomized subjects) completed the study through Week 204.</p><p>&nbsp;</p><p><em>Key efficacy outcomes</em></p><p>In AS001 clinical trial, at Week&nbsp;12 ASAS20 responses were achieved by 58% of patients receiving Cimzia 200&nbsp;mg every 2&nbsp;weeks and 64% of patients receiving Cimzia 400&nbsp;mg every 4&nbsp;weeks as compared to 38% of patients receiving placebo (p&lt;0.01). In the overall population, the percentage of ASAS20 responders was clinically relevant and significantly higher for the Cimzia 200&nbsp;mg every 2&nbsp;weeks and Cimzia 400&nbsp;mg every 4&nbsp;weeks treatment groups compared to placebo group at every visit from Week 1 through Week&nbsp;24 (p&le;0.001 at each visit). At Weeks&nbsp;12 and 24, the percentage of subjects with an ASAS40 response was greater in the Cimzia-treated groups compared to placebo.</p><p>&nbsp;</p><p>Similar results were achieved in both the ankylosing spondylitis and non-radiographic axial spondyloarthritis subpopulations. In women, ASAS20 responses were not statistically significantly different from placebo until after the Week 12 time point.</p><p>&nbsp;</p><p>Improvements in ASAS5/6, Partial Remission and BASDAI‑50 were statistically signficant at Week&nbsp;12 and Week&nbsp;24 and were sustained up to Week&nbsp;48 in the overall popualtion as well as in the subpopulations. Key efficacy outcomes from the AS001 clinical trial are shown in Table ‑8. Among patients remaining in the study, improvements in all afore-mentioned&nbsp; key efficacy outcomes were maintained through Week 204 in the overall population as well as in the subpopulations.</p><p>&nbsp;</p><p><strong>Table&nbsp;8 Key efficacy outcomes in AS001 clinical trial (percent of patients)</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Parameters</p></td><td colspan="2" style="vertical-align:top"><p><strong>Ankylosing spondylitis</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Non-radiographic axial spondyloarthritits</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;Axial spondyloarthritis Overall Population</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Placebo</p><p>N=57</p></td><td style="vertical-align:top"><p>Cimzia</p><p>all dosing regimens<sup>(a)</sup></p><p>N=121</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=50</p></td><td style="vertical-align:top"><p>Cimzia all dosing regimens<sup>(a)</sup></p><p>N=97</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=107</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cimzia all dosing regimens<sup>(a)</sup></p><p>N=218</p></td></tr><tr><td style="vertical-align:top"><p><strong>ASAS20<sup>(b,c)</sup></strong></p><p>Week 12</p><p>Week 24</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>37%</p><p>33%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>60%*</p><p>69%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>40%</p><p>24%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>61%*</p><p>68%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>38%</p><p>29%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>61%**</p><p>68%**</p></td></tr><tr><td style="vertical-align:top"><p><strong>ASAS40<sup>(c,d)</sup></strong></p><p>Week 12</p><p>Week 24</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19%</p><p>16%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>45%**</p><p>53%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16%</p><p>14%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>47%**</p><p>51%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>18%</p><p>15%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>46%**</p><p>52%**</p></td></tr><tr><td style="vertical-align:top"><p><strong>ASAS 5/6<sup>(c,d)</sup></strong></p><p>Week 12</p><p>Week 24</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9%</p><p>5%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>42%**</p><p>40%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8%</p><p>4%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>44%**</p><p>45%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8%</p><p>5%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>43%**</p><p>42%**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Partial remission<sup>(c,d)</sup></strong></p><p>Week 12</p><p>Week 24</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2%</p><p>7%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>20%**</p><p>28%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>6%</p><p>10%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>29%**</p><p>33%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4%</p><p>9%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>24%**</p><p>30%**</p></td></tr><tr><td style="vertical-align:top"><p><strong>BASDAI 50<sup>(c,d)</sup></strong></p><p>Week 12</p><p>Week 24</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11%</p><p>16%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>41%**</p><p>49%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16%</p><p>20%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>49%**</p><p>57%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>13%</p><p>18%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>45%**</p><p>52%**</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>(a)</sup> Cimzia all dosing regimen = data from Cimzia 200 mg administered every 2 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4 plus Cimzia 400 mg administered every 4 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4</p><p><sup>(b)</sup> Results are from the randomized set</p><p><sup>(c)</sup> Wald p-values are quoted for the comparison of treatments using logistic regression with factors for treatment and region.</p><p><sup>(d)</sup> Full Analysis Set</p><p>NA = not available</p><p>*p&le;0.05, Cimzia vs placebo</p><p>**p&lt;0.001, Cimzia vs placebo</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Spinal mobility</em></p><p>Spinal mobility was assessed in the double-blind, placebo-controlled period by using BASMI at several time points including Baseline, Week&nbsp;12 and Week&nbsp;24. Clinically meaningful and statistically significant differences in Cimzia‑treated patients compared with placebo‑treated patients were demonstrated at each post-baseline visit. The difference from placebo tended to be greater in nr‑axSpA than in the AS subpopulation which may be due to less chronic structural damage in nr‑axSpA patients.</p><p>The improvement in BASMI linear score achieved at Week 24 was<strong> </strong>maintained through Week 204 for patients who remained in the study.</p><p>&nbsp;</p><p><em>Physical function response and health-related outcomes </em></p><p>In the AS001 clinical trial, Cimzia‑treated patients reported significant improvements in physical function as assessed by the BASFI and in pain as assessed by the Total and Nocturnal Back Pain NRS scales as compared to placebo. Cimzia-treated patients reported significant improvements in tiredness (fatigue) as reported by the BASDAI‑fatigue item and in health-related quality of life as measured by the ankylosing spondylitis QoL (ASQoL) and the SF‑36 Physical and Mental Component Summaries and all domain scores as compared to placebo. Cimzia‑treated patients reported significant improvements in axial spondyloarthritis-related productivity at work and within household, as reported by the Work Productivity Survey as compared to placebo. For patients remaining in the study, improvements in all afore-mentioned outcomes were largely maintained through Week 204.</p><p>&nbsp;</p><p><em>Inhibition of inflammation in Magnetic Resonance Imaging (MRI)</em></p><p>In an imaging sub-study including 153 patients, signs of inflammation were assessed by MRI at week&nbsp;12 and expressed as change from baseline in SPARCC (Spondyloarthritis Research Consortium of Canada) score for sacroiliac joints and ASspiMRI-a score in the Berlin modifications for the spine. At week 12, significant inhibition of inflammatory signs in both sacroiliac joints and the spine was observed in the Cimzia-treated patients (all dose group), in the overall axial spondyloarthritis population as well as in the sub-populations of ankylosing spondylitis and non-radiographic axial spondyloarthritis.</p><p>Among patients remaining in the study, who had both baseline values and week 204 values, inhibition of inflammatory signs in both the sacroiliac joints (n=72) and&nbsp; spine (n=82) was largely maintained through Week 204 in the overall axial spondyloarthritis population as well as in both the AS and the nr-axSpA subpopulations.</p><p>&nbsp;</p><p><u>Non-radiographic axial spondyloarthritis (nr-axSpA)</u></p><p>The efficacy and safety of Cimzia were assessed in a 52 weeks multicenter, randomized, double-blind, placebo-controlled study (AS0006) in 317 patients &ge;18 years of age with adult-onset axial spondyloarthritis and back pain for at least 12 months. Patients had to fulfil ASAS criteria for nr- axSpA (not including family history and good response to NSAIDs), and have had objective signs of inflammation indicated by C-reactive protein (CRP) levels above the upper limit of normal and/or sacroiliitis on magnetic resonance imaging (MRI), indicative of inflammatory disease [positive CRP (&gt; ULN) and/or positive MRI], but without definitive radiographic evidence of structural damage on sacroiliac joints. Patients had active disease as defined by the BASDAI &ge;4, and spinal pain &ge;4 on a 0 to 10 NRS.&nbsp; Patients must have been intolerant to or had an inadequate response to at least two NSAIDs.&nbsp; Patients were treated with placebo or a loading dose of Cimzia 400 mg at Weeks 0, 2 and 4 followed by 200 mg of Cimzia every 2 weeks.&nbsp; Utilization and dose adjustment of standard of care medication (SC) (e.g., NSAIDs, DMARDs, corticosteroids, analgesics) were permitted at any time. The primary efficacy variable was the Ankylosing Spondylitis Disease Activity Score major improvement (ASDAS-MI) response at Week 52. ASDAS-MI response was defined as an ASDAS reduction (improvement) &ge; 2.0 relative to baseline or as reaching the lowest possible score. ASAS 40 was a secondary endpoint.&nbsp;</p><p>At baseline, 37 % and 41% of patients had high disease activity (ASDAS &ge;2.1, &le;3.5) and 62% and 58% of patient had very high disease activity (ASDAS &gt;3.5) in the CIMZIA group and placebo group respectively.</p><p><em>Clinical response</em></p><p>Study AS0006, performed in subjects without radiographic signs of inflammation in the SI joints, confirmed the effect previously demonstrated in this subgroup in the AS001 study.</p><p>At Week 52, a statistically significant greater proportion of patients treated with Cimzia achieved ASDAS-MI response compared to patients treated with placebo. Cimzia-treated patients also had improvements compared to placebo in multiple components of axial spondyloarthritis disease activity, including CRP. At both Week 12 and 52, ASAS 40 responses were significantly greater than placebo. Key results are presented in Table 9.</p><p>&nbsp;</p><p><strong>Table 9: ASDAS-MI and ASAS 40 responses in AS0006 (percent of patients)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Parameters</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N= 158</strong></p></td><td style="vertical-align:top"><p><strong>Cimzia<sup>a</sup> 200 mg </strong><strong>every 2 weeks</strong></p><p><strong>N= 159</strong></p></td></tr><tr><td style="vertical-align:top"><p>ASDAS-MI</p><p>Week 52</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>47%*</p></td></tr><tr><td style="vertical-align:top"><p>ASAS 40</p><p>Week 12</p><p>&nbsp;</p><p>Week 52</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11%</p><p>&nbsp;</p><p>16%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>48%*</p><p>&nbsp;</p><p>57%*</p></td></tr></tbody></table><p><sup>a </sup>Cimzia administered every 2 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4</p><p>* p&lt;0.001</p><p>All percents reflect the proportion of patients who responded in the full analysis set.</p><p>&nbsp;</p><p>&nbsp;</p><p>At Week 52, the percentage of patients achieving ASDAS inactive disease (ASDAS &lt; 1.3) was 36.4 % for the Cimzia group compared to 11.8 % for the placebo group.</p><p>&nbsp;</p><p>At Week 52, patients treated with Cimzia showed a clinical meaningful improvement in the MASES compared to placebo (LS mean change from baseline -2.4; -0.2 respectively).</p><p>&nbsp;</p><p><em><u>Psoriatic arthritis</u></em></p><p>The efficacy and safety of Cimzia were assessed in a multicentre, randomised, double-blind, placebo controlled clinical trial (PsA001) in 409&nbsp;patients &ge;&nbsp;18&nbsp;years of age with adult-onset active psoriatic arthritis for at least 6&nbsp;months as defined by the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria. Patients had &ge;&nbsp;3 swollen and tender joints and increased acute phase reactants. Patients also had active psoriatic skin lesions or a documented history of psoriasis and had failed 1 or more DMARDs. Previous treatment with one TNF‑antagonist was allowed and 20% of patients had prior TNF‑antagonist exposure. Patients received a loading dose of Cimzia 400&nbsp;mg at Weeks&nbsp;0, 2 and 4 (for both treatment arms) or placebo followed by either Cimzia 200&nbsp;mg every 2&nbsp;weeks or 400&nbsp;mg every 4&nbsp;weeks or placebo every 2&nbsp;weeks. Patients receiving concomitant NSAIDs and conventional&nbsp; DMARDs were 72.6% and 70.2% respectively. The two primary endpoints were the percentage of patients achieving ACR&nbsp;20 response at Week&nbsp;12 and change from baseline in modified Total Sharp Score (mTSS) at Week&nbsp;24. Efficacy and safety of Cimzia in patients with PsA whose predominant symptoms were sacroiliitis or axial spondyloarthritis have not been separately analysed.</p><p>The 24-week double-blind placebo controlled treatment period of the study was followed&nbsp; by a 24-week dose-blind treatment period and an 168-week open-label treatment period . The maximum duration of the study was 216 weeks. All patients received&nbsp; Cimzia in both the dose-blind and open-label follow-up periods. A total of 264 subjects (64.5%) completed the study through Week 216.</p><p>&nbsp;</p><p><em>ACR response</em></p><p>Cimzia-treated patients had a statistically significant higher ACR&nbsp;20 response rate at Week&nbsp;12 and Week&nbsp;24 compared with placebo-treated patients (p&lt;0.001). The percentage of ACR&nbsp;20 responders was clinically relevant for the Cimzia 200&nbsp;mg every 2&nbsp;weeks and Cimzia 400&nbsp;mg every 4&nbsp;weeks treatment groups compared to placebo group at every visit after baseline through Week&nbsp;24 (nominal p&le;0.001 at each visit). Cimzia treated patients also had significant improvements in ACR&nbsp;50 and 70 response rates. At week&nbsp;12 and 24 improvements in parameters of peripheral activity characteristic of psoriatic arthritis (e.g. number of swollen joints, number of painful/tender joints, dactylitis and enthesitis) were seen in the Cimzia-treated patients (nominal p-value p&lt;0.01).</p><p>Key efficacy outcomes from the PsA001 clinical trial are shown in Table 10.</p><p>&nbsp;</p><p><strong>Table&nbsp;10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Key efficacy outcomes in PsA001 clinical trial (percent of patients)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Response</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=136</strong></p></td><td style="vertical-align:top"><p><strong>Cimzia<sup>(a)</sup>200&nbsp;mg</strong></p><p><strong>Q2W</strong></p><p><strong>N=138</strong></p></td><td style="vertical-align:top"><p><strong>Cimzia<sup>(b)</sup> 400&nbsp;mg</strong></p><p><strong>Q4W</strong></p><p><strong>N=135</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR20</strong></p><p>Week 12</p><p>Week 24</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>24%</p><p>24%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>58%**</p><p>64%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>52%**</p><p>56%**</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR50</strong></p><p>Week 12</p><p>Week 24</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11%</p><p>13%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>36%**</p><p>44%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>33%**</p><p>40%**</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR70</strong></p><p>Week 12</p><p>Week 24</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3%</p><p>4%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>25%**</p><p>28%**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>13%*</p><p>24%**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=86</strong></p></td><td style="vertical-align:top"><p><strong>Cimzia<sup>(a)</sup>200&nbsp;mg</strong></p><p><strong>Q2W</strong></p><p><strong>N=90</strong></p></td><td style="vertical-align:top"><p><strong>Cimzia<sup>(b)</sup> 400&nbsp;mg</strong></p><p><strong>Q4W</strong></p><p><strong>N=76</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 75</strong><sup> (c)</sup></p><p><strong>Week 12</strong></p><p><strong>Week 24</strong></p><p><strong>Week 48</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>14%</p><p>15%</p><p>N/A</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>47%***</p><p>62%***</p><p>67%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>47%***</p><p>61%***</p><p>62%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong><sup>(</sup></strong><sup>a) </sup>Cimzia administered every 2&nbsp;weeks preceded by a loading dose of 400&nbsp; mg at Weeks&nbsp;0, 2 and 4</p><p><sup>(b)</sup> Cimzia administered every 4&nbsp;weeks preceded by a loading dose of 400&nbsp;mg at Weeks&nbsp;0, 2 and 4</p><p><sup>(c)</sup> In subjects with at least 3% psoriasis BSA at Baseline</p><p>*p&lt;0.01, Cimzia vs placebo</p><p>**p&lt;0.001, Cimzia vs placebo</p><p>***p&lt;0.001(nominal), Cimzia vs placebo</p><p>Results are from the randomized set.Treatment Difference: Cimzia 200&nbsp;mg-placebo, Cimzia 400&nbsp;mg-</p><p>placebo (and corresponding 95% CI and p‑value) are estimated using a standard two‑sided Wald</p><p>asymptotic standard errors test. Non-responder Imputation (NRI) is used for patients who escaped therapy or had missing data.</p></td></tr></tbody></table><p>&nbsp;</p><p>Among 273&nbsp;patients initially randomised to Cimzia 200&nbsp;mg every 2&nbsp;weeks and Cimzia 400&nbsp;mg every 4&nbsp;weeks, 237 (86.8%) were still on this treatment at Week&nbsp;48. &nbsp;Of the 138&nbsp;patients randomised to Cimzia 200&nbsp;mg every 2&nbsp;weeks, 92, 68 and 48 had an ACR&nbsp;20/50/70 response, at Week 48, respectively. Of the 135 patients randomised to Cimzia 400&nbsp;mg every 4&nbsp;weeks, 89, 62 and 41 patients had an ACR&nbsp;20/50/70 response, respectively.</p><p>&nbsp;</p><p>Among patients remaining in the study, ACR 20, 50 and 70 response rates were maintained through Week 216. This was also the case for the other parameters of peripheral activity (e.g. number of swollen joints, number of painful/tender joints, dactylitis and enthesitis). &nbsp;</p><p>&nbsp;</p><p><em>Radiographic response</em></p><p>In PsA001 clinical trial, inhibition of progression of structural damage was assessed radiographically and expressed as the change in modified total Sharp score (mTSS) and its components, the Erosion Score (ES) and Joint Space Narrowing score (JSN) at Week&nbsp;24, compared to baseline. The mTSS Score was modified for psoriatic arthritis by addition of hand distal interphalangeal joints. Cimzia treatment inhibited the radiographic progression compared with placebo treatment at Week&nbsp;24 as measured by change from baseline in total mTSS Score (LS mean [&plusmn;SE] score was 0.28&nbsp;[&plusmn;0.07] in the placebo group compared with 0.06&nbsp;[&plusmn;0.06] in the Cimzia all doses group; p=0.007). Inhibition of radiographic progression was maintained with Cimzia treatment up to Week&nbsp;48 in the subset of patients at higher risk of radiographic progression (patients with a Baseline mTSS score of &gt;&nbsp;6). Inhibition of radiographic progression was further maintained up to Week 216 for the patients who remained in the study.</p><p>&nbsp;</p><p><em>Physical function response and health-related outcomes</em></p><p>In PsA001 clinical trial, Cimzia-treated patients reported significant improvements in physical function as assessed by the Health Assessment Questionnaire &ndash; Disability Index (HAQ‑DI), in pain as assessed by the PAAP and in tiredness (fatigue) as reported by the Fatigue Assessment Scale (FAS) as compared to placebo. Cimzia-treated patients reported significant improvements in health-related quality of life as measured by the psoriatic arthritis QoL&nbsp;(PsAQoL) and the SF‑36 Physical and Mental Components and in psoriatic arthritis-related productivity at work and within household, as reported by the Work Productivity Survey compared to placebo. Improvements in all afore-mentioned outcomes were maintained through Week 216.</p><p>&nbsp;</p><p><em><u>Plaque psoriasis</u></em></p><p>The efficacy and safety of Cimzia were assessed in two placebo-controlled studies (CIMPASI-1 and CIMPASI-2) and one placebo- and active-controlled study (CIMPACT) in patients &ge;18 years of age with moderate to severe chronic plaque psoriasis for at least 6 months. Patients had a Psoriasis Area and Severity Index (PASI) score &ge; 12, body surface area (BSA) involvement of &ge; 10%, Physician Global Assessment (PGA) of &ge; 3, and were candidates for systemic therapy and/or phototherapy and/or chemophototherapy. Patients who were &lsquo;primary&rsquo; non-responders on any prior biologic therapy (defined as no response within the first 12 weeks of treatment) were excluded from the phase III studies (CIMPASI-1, CIMPASI-2 and CIMPACT). The efficacy and safety of Cimzia were evaluated versus etanercept in the CIMPACT study.</p><p>&nbsp;</p><p>In studies CIMPASI-1 and CIMPASI-2 the co-primary efficacy endpoints were the proportion of patients achieving PASI 75 and PGA &ldquo;clear&rdquo; or &ldquo;almost clear&rdquo; (with at least a 2-point reduction from baseline) at Week 16. In the CIMPACT study, the primary efficacy endpoint was the proportion of patients achieving PASI 75 at Week 12. PASI75 and PGA at Week 16 were key secondary endpoints. PASI 90 at Week 16 was a key secondary endpoint in all 3 studies.</p><p><em>&nbsp;</em></p><p>CIMPASI-1 and CIMPASI-2 evaluated 234 patients and 227 patients respectively. In both studies patients were randomized&nbsp; to receive placebo or Cimzia 200 mg every 2 weeks (following a loading dose&nbsp; of Cimzia 400 mg at Weeks 0, 2 and 4) or Cimzia 400 mg every 2 weeks. At week 16, patients randomized to Cimzia who achieved a PASI 50 response continued to receive Cimzia up to Week 48 at the same randomized dose. Patients originally randomized to placebo that achieved a PASI 50 response but not a PASI 75 response at Week 16 received Cimzia 200 mg every 2 weeks (with a loading dose of&nbsp; Cimzia 400 mg at Weeks 16, 18, and 20). Patients with an inadequate response at Week 16 (PASI 50 non-responders) were eligible to receive Cimzia 400 mg every 2 weeks in an open-label manner for a maximum of 128 weeks.</p><p>&nbsp;</p><p>The CIMPACT study evaluated 559 patients. Patients were randomized to receive placebo, or Cimzia 200 mg every 2 weeks (following a loading dose of Cimzia 400 mg at Weeks 0, 2 and 4), or Cimzia 400 mg every 2 weeks up to Week 16, or etanercept 50 mg twice weekly, up to Week 12. Patients originally randomized to Cimzia who achieved a PASI75 response at Week 16 were re-randomized based on their original dosing schedule. Patients on Cimzia 200 mg every 2 weeks were re-randomized to Cimzia 200 mg every 2 weeks, Cimzia 400 mg every 4 weeks or placebo. Patients on Cimzia 400 mg every 2 weeks were re-randomized to Cimzia 400 mg every 2 weeks, Cimzia 200 mg every 2 weeks, or placebo. Patients were evaluated in a double-blind placebo-controlled manner through Week 48. All subjects who did not achieve a PASI 75 response at Week 16 entered an escape arm and received Cimzia 400 mg every 2 weeks in an open-label manner for a maximum of 128 weeks.</p><p>&nbsp;</p><p>In all three studies, the blinded 48-week maintenance period was followed by a 96-week open-label treatment period for the patients who were PASI 50 responders at Week 48. All these patients, including those receiving Cimzia 400 mg every 2 weeks, started the open-label period at Cimzia 200 mg every 2 weeks.</p><p>&nbsp;</p><p>Patients were predominantly men (64%) and Caucasian (94%), with a mean age of 45.7 years (18 to 80</p><p>years); of these, 7.2% were &ge; 65 years of age. Of the 850 patients randomized to receive placebo or Cimzia in these placebo-controlled studies, 29% of patients were na&iuml;ve to prior systemic therapy for the treatment of psoriasis. 47% had received prior phototherapy or chemophototherapy, and 30% had received prior biologic therapy for the treatment of psoriasis. Of the 850 patients, 14% had received at least one TNF-antagonist,&nbsp; 13% had received an anti-IL-17, and 5% had received an anti-IL 12/ 23.&nbsp; Eighteen percent of patients reported a history of psoriatic arthritis at baseline. The mean PASI score at baseline was 20 and ranged from 12 to 69. The baseline PGA score ranged from moderate (70%) to severe (30%). Mean baseline BSA was 25% and ranged from 10% to 96%.</p><p>&nbsp;</p><p><em>Clinical response at Week 16 and 48</em></p><p>The key results of CIMPASI-1 and CIMPASI-2 studies are presented in Table 11.</p><p>&nbsp;</p><p><strong>Table 11: Clinical response in studies CIMPASI-1 and CIMPASI-2 at Week 16 and Week 48</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Week 16</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 48</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>CIMPASI-1</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p><p>&nbsp;</p><p>N=51</p></td><td style="vertical-align:top"><p>Cimzia 200 mg Q2W<sup> a)</sup></p><p>N=95</p></td><td style="vertical-align:top"><p>Cimzia 400 mg Q2W</p><p>N=88</p></td><td style="vertical-align:top"><p>Cimzia 200 mg Q2W</p><p>N=95</p></td><td style="vertical-align:top"><p>Cimzia 400 mg Q2W</p><p>N=88</p></td></tr><tr><td style="vertical-align:top"><p>PGA clear or almost clear<sup>b)</sup></p></td><td style="vertical-align:top"><p>4.2%</p></td><td style="vertical-align:top"><p>47.0%*</p></td><td style="vertical-align:top"><p>57.9%*</p></td><td style="vertical-align:top"><p>52.7%</p></td><td style="vertical-align:top"><p>69.5%</p></td></tr><tr><td style="vertical-align:top"><p>PASI 75</p></td><td style="vertical-align:top"><p>6.5%</p></td><td style="vertical-align:top"><p>66.5%*</p></td><td style="vertical-align:top"><p>75.8%*</p></td><td style="vertical-align:top"><p>67.2%</p></td><td style="vertical-align:top"><p>87.1%</p></td></tr><tr><td style="vertical-align:top"><p>PASI 90</p></td><td style="vertical-align:top"><p>0.4%</p></td><td style="vertical-align:top"><p>35.8%*</p></td><td style="vertical-align:top"><p>43.6%*</p></td><td style="vertical-align:top"><p>42.8%</p></td><td style="vertical-align:top"><p>60.2%</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>CIMPASI-2</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p><p>&nbsp;</p><p>N=49</p></td><td style="vertical-align:top"><p>Cimzia 200 mg Q2W<sup> a)</sup></p><p>N=91</p></td><td style="vertical-align:top"><p>Cimzia 400 mg Q2W</p><p>N=87</p></td><td style="vertical-align:top"><p>Cimzia 200 mg Q2W</p><p>N= 91</p></td><td style="vertical-align:top"><p>Cimzia 400 mg Q2W</p><p>N= 87</p></td></tr><tr><td style="vertical-align:top"><p>PGA clear or almost clear<sup>b)</sup></p></td><td style="vertical-align:top"><p>2.0%</p></td><td style="vertical-align:top"><p>66.8%*</p></td><td style="vertical-align:top"><p>71.6%*</p></td><td style="vertical-align:top"><p>72.6%</p></td><td style="vertical-align:top"><p>66.6%</p></td></tr><tr><td style="vertical-align:top"><p>PASI 75</p></td><td style="vertical-align:top"><p>11.6%</p></td><td style="vertical-align:top"><p>81.4%*</p></td><td style="vertical-align:top"><p>82.6%*</p></td><td style="vertical-align:top"><p>78.7%</p></td><td style="vertical-align:top"><p>81.3%</p></td></tr><tr><td style="vertical-align:top"><p>PASI 90</p></td><td style="vertical-align:top"><p>4.5%</p></td><td style="vertical-align:top"><p>52.6%*</p></td><td style="vertical-align:top"><p>55.4%*</p></td><td style="vertical-align:top"><p>59.6%</p></td><td style="vertical-align:top"><p>62.0%</p></td></tr></tbody></table><p><sup>a)</sup> Cimzia 200 mg administered every 2 weeks preceded by a loading dose of 400 mg at Week 0, 2, 4.</p><p><sup>b)</sup> PGA 5 category scale. Treatment success of &ldquo;clear&rdquo; (0) or &ldquo;almost clear&rdquo;(1) consisted of no signs of psoriasis or normal to pink coloration of lesions, no thickening of the plaque, and none to minimal focal scaling.</p><p>* Cimzia vs placebo: p&lt; 0.0001.</p><p>Response rates and p-values for PASI and PGA were estimated based on a logistic regression model where missing data were imputed using multiple imputation based on the MCMC method. Subject who escaped or withdrew (based on not achieving PASI 50 response) were treated as non-responders at Week 48.</p><p>Results are from the Randomized Set.</p><p>&nbsp;</p><p>The key results of the CIMPACT trial are presented in Table 12.</p><p>&nbsp;</p><p><strong>Table 12: Clinical response in CIMPACT study at Week 12 and Week 16</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Week 12</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Week 16</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=57</p></td><td style="vertical-align:top"><p>Cimzia 200 mg Q2W<sup> a)</sup></p><p>N=165</p></td><td style="vertical-align:top"><p>Cimzia 400 mg Q2W</p><p>N=167</p></td><td style="vertical-align:top"><p>Etanercept 50 mg BiW</p><p>N=170</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=57</p></td><td style="vertical-align:top"><p>Cimzia 200 mg Q2W</p><p>N=165</p></td><td style="vertical-align:top"><p>Cimzia 400 mg</p><p>Q2W</p><p>N=167</p></td></tr><tr><td style="vertical-align:top"><p>PASI 75</p></td><td><p>5%</p></td><td><p>61.3%*<sup>,&sect;</sup></p></td><td><p>66.7%*<sup>,&sect;&sect;</sup></p></td><td style="vertical-align:top"><p>53.3%</p></td><td><p>3.8%</p></td><td><p>68.2%*</p></td><td><p>74.7%*</p></td></tr><tr><td style="vertical-align:top"><p>PASI 90</p></td><td><p>0.2%</p></td><td><p>31.2%*</p></td><td><p>34.0%*</p></td><td style="vertical-align:top"><p>27.1%</p></td><td><p>0.3%</p></td><td><p>39.8%*</p></td><td><p>49.1%*</p></td></tr><tr><td style="vertical-align:top"><p>PGA clear or almost clear <sup>b)</sup></p></td><td><p>1.9%</p></td><td><p>39.8%**</p></td><td><p>50.3%*</p></td><td><p>39.2%</p></td><td><p>3.4%</p></td><td><p>48.3%*</p></td><td><p>58.4%*</p></td></tr></tbody></table><p><sup>a)</sup> Cimzia 200 mg administered every 2 weeks preceded by a loading dose of 400 mg at Week 0, 2, 4.</p><p><sup>b)</sup> PGA 5 category scale. Treatment success of &ldquo;clear&rdquo; (0) or &ldquo;almost clear&rdquo;(1) consisted of no signs of psoriasis or normal to pink coloration of lesions, no thickening of the plaque, and none to minimal focal scaling.</p><p>* Cimzia vs placebo: p&lt; 0.0001.</p><p><sup>&sect;</sup> Cimzia 200 mg every 2 weeks versus etanercept 50 mg twice weekly demonstrated non-inferiority (difference between etanercept and Cimzia 200 mg every 2 weeks was 8.0%, 95% CI -2.9, 18.9, based on a pre-specified non-inferiority margin of 10%).</p><p><sup>&sect;&sect; </sup>Cimzia 400 mg every 2 weeks versus etanercept 50 mg twice weekly demonstrated superiority (p&lt;0.05)</p><p>** Cimzia vs Placebo p &lt; 0.001. Response rates and p-values based on a logistic regression model.</p><p>Missing data were imputed using multiple imputation based on the MCMC method. Results are from the Randomized Set.</p><p>&nbsp;</p><p>In all 3 studies, the PASI 75 response rate was significantly greater for Cimzia compared to placebo starting at Week 4.</p><p>&nbsp;</p><p>Both doses of Cimzia demonstrated efficacy compared to placebo regardless of age, gender, body weight, BMI, psoriasis disease duration, previous treatment with systemic therapies and previous treatment with biologics.</p><p>&nbsp;</p><p><em>Maintenance of response </em></p><p>In&nbsp;an integrated analysis of&nbsp; CIMPASI-1 and CIMPASI-2, among patients who were PASI 75 responders at Week 16 and received Cimzia 400 mg every 2 weeks (N=134 of 175 randomised subjects) or Cimzia 200 mg every 2 weeks (N=132 of 186 randomised subjects), the maintenance of response at Week 48 was 98.0% and 87.5%, respectively. Among patients who were PGA clear or almost clear at Week 16 and received Cimzia 400 mg every 2 weeks (N=103 of 175) or Cimzia 200 mg every 2 weeks (N=95 of 186), the maintenance of response at Week 48 was 85.9% and 84.3% respectively.</p><p>&nbsp;</p><p>After an additional 96 weeks of open-label treatment (Week 144) the maintenance of response was evaluated. Twenty-one percent of all randomised subjects were lost to follow-up before Week 144. Approximately 27% of completer study subjects who entered the open-label treatment between weeks 48 to 144 on Cimzia 200 mg every 2 weeks had their dose increased to Cimzia 400 mg every 2 weeks for maintenance of response. In an analysis in which all patients with treatment failures were considered non-responders, the maintenance of response of the Cimzia 200 mg every 2 weeks treatment group for the respective endpoint, after an additional 96 weeks of open-label therapy, was 84.5% for PASI 75 for study subjects who were responders at Week 16&nbsp; and 78.4% for PGA clear or almost clear. The maintenance of response of the Cimzia 400 mg every 2 weeks treatment group, who entered the open-label period at Cimzia 200 mg every 2 weeks, was 84.7% for PASI 75 for study subjects who were responders at Week 16 and 73.1% for PGA clear or almost clear.</p><p>&nbsp;</p><p>These response rates were based on a logistic regression model where missing data were imputed over 48 or 144 weeks using multiple imputation (MCMC method) combined with NRI for treatment failures.</p><p>&nbsp;</p><p>In the CIMPACT study, among PASI 75 responders at Week 16 who received Cimzia 400 mg every 2 weeks and were re-randomized to either Cimzia 400 mg every 2 weeks, Cimzia 200 mg every 2 weeks, or placebo, there was a higher percentage of PASI 75 responders at Week 48 in the Cimzia groups as compared to placebo (98.0%, 80.0%, and 36.0%, respectively). Among PASI75 responders at Week 16 who received Cimzia 200 mg every 2 weeks and were re-randomized to either Cimzia 400 mg every 4 weeks, Cimzia 200 mg every 2 weeks, or placebo, there was also a higher percentage of PASI 75 responders at Week 48 in the Cimzia groups as compared to placebo (88.6%, 79.5%, and 45.5%, respectively). Non-responder imputation was used for missing data.</p><p>&nbsp;</p><p><em>Quality of life / Patient reported outcomes</em></p><p>&nbsp;</p><p>Statistically significant improvements at Week 16 (CIMPASI-1 and CIMPASI-2) from baseline compared to placebo were demonstrated in the DLQI (Dermatology Life Quality Index). Mean decreases (improvements) in DLQI from baseline ranged from -8.9 to -11.1 with Cimzia 200 mg every 2 weeks, from -9.6 to -10.0 with Cimzia 400 mg every 2 weeks, versus -2.9 to -3.3 for placebo at Week 16.</p><p>&nbsp;</p><p>In addition, at Week 16, Cimzia treatment was associated with a greater proportion of patients achieving a DLQI score of&nbsp; 0 or 1 (Cimzia 400 mg every 2 weeks, 45.5% and 50.6% respectively; Cimzia 200 mg every 2 weeks, 47.4% and 46.2% respectively, versus placebo, 5.9% and 8.2% respectively).</p><p>&nbsp;</p><p>Improvements in DLQI score were sustained or slightly decreased through Week 144.</p><p>&nbsp;</p><p>Cimzia-treated patients reported greater improvements compared to placebo in the Hospital Anxiety and Depression Scale (HADS)-D.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p><em><u>&nbsp;</u></em></p><p><em><u>Rheumatoid arthritis</u></em></p><p>The overall percentage of patients with antibodies to Cimzia detectable on at least 1 occasion was 9.6% in RA placebo-controlled trials. Approximately one-third of antibody-positive patients had antibodies with neutralising activity <em>in vitro</em>. Patients treated with concomitant immunosuppressants (MTX) had a lower rate of antibody development than patients not taking immunosuppressants at baseline. Antibody formation was associated with lowered drug plasma concentration and in some patients, reduced efficacy.</p><p>&nbsp;</p><p>In 2 long-term (up to 5 years of exposure) open-label studies, the overall percentage of patients with antibodies to Cimzia detectable on at least one occasion was 13% (8.4% of the overall patients had transient formation of antibodies and an additional 4.7% had persistent formation of antibodies to Cimzia). The overall percentage of patients that were antibody positive with a persistent reduction of drug plasma concentration was estimated to be 9.1%. Similar to the placebo-controlled studies, antibody positivity was associated with reduced efficacy in some patients.</p><p>&nbsp;</p><p>A pharmacodynamic model based on the Phase III trial data predicts that around 15% of the patients develop antibodies in 6&nbsp;months at the recommended dose regimen (200&nbsp;mg every 2&nbsp;weeks following a loading dose) without MTX co-treatment. This number decreases with increasing doses of concomitant MTX treatment. These data are reasonably in agreement with observed data.</p><p>&nbsp;</p><p><em><u>Axial spondyloarthritis</u></em></p><p>The overall percentage of patients with antibodies to Cimzia detectable on at least one occasion up to Week&nbsp;24 was 4.4% in the AS001 phase III placebo controlled trial in patients with axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis subpopulations). Antibody formation was associated with lowered drug plasma concentration.</p><p>&nbsp;</p><p>Over the course of the entire study&nbsp; (up to 192 weeks), the overall percentage of patients with antibodies to Cimzia detectable on at least one occasion was 9.6% &nbsp;(4.8% had transient formation and an additional 4.8% &nbsp;had persistent formation of antibodies to Cimzia). The overall percentage of patients that were antibody positive with a persistent reduction of drug plasma concentration was estimated to be 6.8%.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Psoriatic arthritis</u></em></p><p>The overall percentage of patients with antibodies to Cimzia detectable on at least one occasion up to Week&nbsp;24 was 11.7% in the Phase III placebo-controlled trial in patients with psoriatic arthritis. Antibody formation was associated with lowered drug plasma concentration.</p><p>&nbsp;</p><p>Over the course of the entire study&nbsp; (up to 4 years of exposure), the overall percentage of patients with antibodies to Cimzia detectable on at least one occasion was 17.3% (8.7% had transient formation and an additional 8.7% had persistent formation of antibodies to Cimzia). The overall percentage of patients that were antibody positive with a persistent reduction of drug plasma concentration was estimated to be 11.5%.</p><p>&nbsp;</p><p><em><u>Plaque psoriasis</u></em></p><p>In the Phase III placebo- and active-controlled studies, the percentages of patients who were positive for&nbsp; antibodies to Cimzia on at least one occasion during treatment up to Week 48 were 8.3 % (22/265) and&nbsp; 19.2% (54/281) for the Cimzia 400 mg every 2 weeks and Cimzia 200 mg every 2 weeks respectively. In CIMPASI-1 and CIMPASI-2, sixty patients were antibody positive, 27 of these patients were evaluable for neutralizing antibodies and tested positive. First occurrences of antibody positivity in the open-label treatment period were observed in 2.8% (19/668) of patients. Antibody positivity was associated with lowered drug plasma concentration and in some patients with reduced efficacy.</p><p>&nbsp;</p><p><em><u>For all indications</u></em></p><p>The data above reflect the percentage of patients whose test results were considered positive for antibodies to Cimzia in an ELISA, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibodies in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medicinal products, and underlying disease. For these reasons, comparison of the incidence of antibodies to Cimzia with the incidence of antibodies to other TNF‑antagonists is not appropriate.</p><p>&nbsp;</p><p><em><u>Non-radiographic AxSpA</u></em></p><p>In the placebo-controlled trial in patients with non-radiographic axial spondyloarthritis, using a more sensitive and drug tolerant assay than in previous trials, the overall incidence of patients who were antibody positive to certolizumab pegol was 97% (248/255 patients) after up to 52 weeks of treatment. Only the highest titers were associated with reduced certolizumab pegol plasma levels, however, no impact on efficacy was observed. About 22% (54/248) of the patients who were anti-certolizumab pegol antibody positive at any time, had antibodies that were classified as neutralizing.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Certolizumab pegol plasma concentrations were broadly dose-proportional. Pharmacokinetics observed in patients with rheumatoid arthritis and psoriasis were consistent with those seen in healthy subjects.</p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>Following subcutaneous administration, peak plasma concentrations of certolizumab pegol were attained between 54 and &nbsp;171&nbsp;hours post-injection. Certolizumab pegol has a bioavailability (F) of approximately 80% (range 76% to 88%) following subcutaneous administration compared to intravenous administration.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The apparent volume of distribution (V/F) was estimated at 8.01&nbsp;l in a population pharmacokinetic analysis of patients with rheumatoid arthritis and at 4.71 l in a population pharmacokinetic analysis of patients with plaque psoriasis.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>PEGylation, the covalent attachment of PEG polymers to peptides, delays the elimination of these entities from the circulation by a variety of mechanisms, including decreased renal clearance, decreased proteolysis, and decreased immunogenicity. Accordingly, certolizumab pegol is an antibody Fab&#39; fragment conjugated with PEG in order to extend the terminal plasma elimination half-life of the Fab&#39; to a value comparable with a whole antibody product. The terminal elimination phase half-life (t<sub>1/2</sub>) was approximately 14 days for all doses tested.</p><p>&nbsp;</p><p>Clearance following subcutaneous dosing was estimated to be 21.0&nbsp;ml/h in a rheumatoid arthritis population pharmacokinetic analysis, with an inter-subject variability of 30.8% (CV) and an inter-occasion variability of 22.0%. When assessed using the previous ELISA method, the presence of antibodies to certolizumab pegol resulted in an approximately three-fold increase in clearance. Compared with a 70&nbsp;kg person, clearance is 29% lower and 38% higher, respectively, in individual RA patients weighing 40&nbsp;kg and 120&nbsp;kg. The clearance following subcutaneous dosing in patients with psoriasis was 14 ml/h with an inter-subject variability of 22.2% (CV).</p><p>&nbsp;</p><p>The Fab&#39; fragment comprises protein compounds and is expected to be degraded to peptides and amino acids by proteolysis. The de-conjugated PEG component is rapidly eliminated from plasma and is to an unknown extent excreted renally.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><em>Renal impairment</em></p><p>Specific clinical trials have not been performed to assess the effect of renal impairment on the pharmacokinetics of certolizumab pegol or its PEG fraction. However, population pharmacokinetic analysis based on subjects with mild renal impairment showed no effect of creatinine clearance. There are insufficient data to provide a dosing recommendation in moderate and severe renal impairment. The pharmacokinetics of the PEG fraction of certolizumab pegol are expected to be dependent on renal function but have not been assessed in patients with renal impairment.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Specific clinical trials have not been performed to assess the effect of hepatic impairment on the pharmacokinetics of certolizumab pegol.</p><p>&nbsp;</p><p><em>Elderly patients (&ge;&nbsp;65&nbsp;years old)</em></p><p>Specific clinical trials have not been performed in elderly patients subjects. However, no effect of age was observed in a population pharmacokinetic analysis in patients with rheumatoid arthritis in which 78 subjects (13.2% of the population) were aged 65 or greater and the oldest subject was aged 83&nbsp;years. No effect of age was observed in a population pharmacokinetic analysis in adult patients with plaque psoriasis.</p><p>&nbsp;</p><p><u>Gender</u></p><p>There was no effect of gender on the pharmacokinetics of certolizumab pegol. As clearance decreases with decreasing body weight, females may generally obtain somewhat higher systemic exposure of certolizumab pegol.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>On the basis of Phase II and Phase III clinical trial data in patients with rheumatoid arthritis, a population exposure-response relationship was established between average plasma concentration of certolizumab pegol during a dosing interval (C<sub>avg</sub>) and efficacy (ACR&nbsp;20 responder definition). The typical C<sub>avg</sub> that produces half the maximum probability of ACR&nbsp;20 response (EC50) was 17&nbsp;&micro;g/ml (95% CI: 10‑23&nbsp;&micro;g/ml). Similarly, on the basis of Phase III clinical trial data in patients with psoriasis, a population exposure-response relationship was established between plasma concentration of certolizumab pegol and PASI with an EC90 of 11.1 &micro;g/ml.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pivotal non-clinical safety studies were conducted in the cynomolgus monkey. In rats and monkeys, at doses higher than those given to humans, histopathology revealed cellular vacuolation, present mainly in macrophages, in a number of organs (lymph nodes, injection sites, spleen, adrenal, uterine, cervix, choroid plexus of the brain, and in the epithelial cells of the choroid plexus). It is likely that this finding was caused by cellular uptake of the PEG moiety. <em>In vitro</em> functional studies of human vacuolated macrophages indicated all functions tested were retained. Studies in rats indicated that &gt;&nbsp;90% of the administered PEG was eliminated in 3&nbsp;months following a single dose, with the urine being the main route of excretion.</p><p>&nbsp;</p><p>Certolizumab pegol does not cross-react with rodent TNF. Therefore, reproductive toxicology studies have been performed with a homologous reagent recognising rat TNF. The value of these data to the evaluation of human risk may be limited. No adverse effects were seen on maternal well-being or female fertility, embryo-foetal and peri- and post-natal reproductive indices in rats using a rodent anti-rat TNF&alpha; PEGylated Fab&#39; (cTN3 PF) following sustained TNF&alpha; suppression. In male rats, reduced sperm motility and a trend of reduced sperm count were observed.</p><p>&nbsp;</p><p>Distribution studies have demonstrated that placental and milk transfer of cTN3 PF to the foetal and neonatal circulation is negligible. Certolizumab pegol does not bind to the human neonatal Fc receptor (FcRn). Data from a human closed-circuit placental transfer model <em>ex vivo</em> suggest low or negligible transfer to the foetal compartment. In addition, experiments of FcRn-mediated transcytosis in cells transfected with human FcRn showed negligible transfer (see section 4.6).&nbsp;</p><p>&nbsp;</p><p>No mutagenic or clastogenic effects were demonstrated in preclinical studies. Carcinogenicity studies have not been performed with certolizumab pegol.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium acetate</p><p>Sodium chloride</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
See also section 6.4 for shelf-life related to storage at room temperature up to a maximum of 25°C.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze.</p><p>Keep the pre-filled syringe in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One ml pre-filled syringe (type I glass) with a plunger stopper (bromobutyl rubber), containing 200&nbsp;mg of certolizumab pegol. The needle shield is styrene butadiene rubber which contains a derivative of natural rubber latex (see section 4.4).</p><p>&nbsp;</p><p>Pack size of 2 pre-filled syringes and 2 alcohol wipes.</p><p>Multipack containing 6 (3 packs of 2) pre-filled syringes and 6 (3 packs of 2) alcohol wipes.</p><p>Multipack containing 10 (5 packs of 2) pre‑filled syringes and 10 (5 packs of 2) alcohol wipes.</p><p>Pack size of 2 pre-filled syringes with needle guard and 2 alcohol wipes (for use by healthcare professionals only).</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Comprehensive instructions for the preparation and administration of Cimzia in a pre-filled syringe are given in the package leaflet.</p><p>This medicinal product is for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Bruxelles
Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                {06/2022}
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>